

CRISPR/Cas9 and Blood Transfusions: Advancing HLA Class I-Deleted Blood Products to Prevent Rejection

Sofia Hall¹, Alexander Wright²

¹ Department of Bioengineering, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran 31261, Saudi Arabia.

² Interdisciplinary Research Center for Hydrogen and Energy Storage (IRC-HES), King Fahd University of Petroleum and Minerals (KFUPM), Dhahran, 31261, Saudi Arabia.

ABSTRACT

In adults, normal hematopoiesis occurs in the bone marrow, producing leukocytes, red blood cells, and platelets. Recently, megakaryocytes have been found in mouse lungs and spleen, where they release platelets by blood flow force. Blood products are used to treat a multitude of diseases and conditions that generate cytopenia. The blood transfusion system must be enhanced due to a drop in blood donors due to low birth rate and changing attitudes among young people, pathogen contamination, and rising demand due to chronic blood diseases that are prevalent among the elderly. Pluripotent stem cells, such as embryonic stem (ES) cells, may proliferate in vitro indefinitely and are a prospective source for blood transfusions to replace blood donations.

Platelet preparations can be maintained at room temperature to sustain platelet function, but only have a statutory expiry date of five days. Platelets are anucleate cells, thus irradiation before blood donation can lessen the risk of iPS cell infection. Effective treatment requires HLA-compatible platelet transfusions, although supply limits often leave patients underserved. CRISPR/Cas9 has made it viable to make HLA class I-deleted blood products to avoid rejection and lower the odds of platelet-expressed human leukocyte antigen Class I cancer-causing iPS cells (HLA-I). This article discusses the production of megakaryocyte cell lines, bioreactors, and scale-up cultures, as well as identifying viable drugs in manufacturing. HLA-null, iPSC-derived platelet products' universal potential will also be explored.

1 INTRODUCTION

Leukocytes, red blood cells, and platelets are all created in the bone marrow during normal hematopoiesis in adults. This process takes place in the bone marrow. On the other hand, fetal hematopoiesis takes place in unique places and at different phases of development than adult hematopoiesis. Primitive hematopoiesis happens briefly in the yolk sac during the early stages of embryo development. Definitive hematopoiesis starts after primary hematopoiesis and moves from the aorta-gonad-mesonephros (AGM) to the liver, and then to the bone marrow. These are the two stages of the development of fetal hematopoiesis. Our bodies are kept alive and protected by our circulatory system, which is responsible for three essential functions: oxygen delivery, coagulation, and immunity. Platelets are anucleate blood cells that play a role in clotting and are released from megakaryocytes in the bone marrow. Platelets are responsible for the clotting process. In typical thrombocytosis, mature megakaryocytes will have an extended cytoplasmic structure that is referred to as the proplatelet. The tip of the proplatelet extends into the bone marrow sinus, which is where it is sheared and changed into a platelet by the circulation (Junt et al., 2007; Kosaki, 2008; Machlus & Italiano, 2013; Thon et al., 2010). (Junt et al., 2007; Kosaki, 2008; Machlus & Italiano, 2013; Thon et al., 2010). (Lefrancais et al., 2017) Recent research has shown that megakaryocytes may be found in the lung and spleen of mice. These cells, when stimulated by the movement of blood, can then produce platelets.

According to Estcourt et al. (2017), blood products obtained from blood donors are utilized in the treatment of a variety of diseases and conditions that can result in cytopenia. On the other hand, the system for blood transfusions needs to be improved because there has been a decline in the number of people willing to donate blood as a result of declining birthrates and shifting attitudes among the younger population. Additionally, there has been an increase in demand because of the prevalence of chronic blood disorders among the elderly. Platelet preparations can be maintained at room temperature without losing their function, although they have a statutory expiration date that is only five days after they are made. As a direct consequence of this, platelet preparations are notoriously difficult to keep in stock. In addition, some individuals have alloantibodies that are directed against platelet-expressed human leukocyte antigen class I (HLA-I). This can lead to a condition known as alloimmune platelet transfusion refractoriness, or allo-PTR (Stanworth et al., 2015). Platelet transfusions that are HLA-compatible are necessary for optimal treatment; yet, supply shortages frequently result in patients not being adequately supplied. Pluripotent stem cells, which include embryonic stem (ES) cells (Thomson, 1998) and induced pluripotent stem (iPS) cells (Takahashi et al., 2007), have the potential to grow in vitro indefinitely and are a prospective source for the development of blood transfusion products that can serve as a replacement for blood donations. Irradiation of platelets prior to blood donation can help lower the risk of cancer caused by iPS cell contamination.

Since platelets are nucleolus-free cells, this risk can be mitigated. In addition, there is the possibility of improving the current blood transfusion system, which is dependent on donors, by using stored iPS cells that are homozygous for HLA in order to maintain a constant supply of HLA-compatible platelets. In more recent times, genetic editing techniques such as the CRISPR/Cas9 approach have made it possible to create HLA class I-deleted blood products in order to prevent rejection (Cong et al., 2013; Mali et al., 2013). This has allowed for the elimination of the need for HLA class I-deleted blood products to be used in transplantation. This paper discusses a number of topics, including the production of megakaryocyte cell lines, bioreactors, and scaled-up cultures, as well as the locating of potentially useful drugs during the manufacturing process. In addition to this, we will talk about the universal applicability of platelet products produced from iPSCs that lack HLA.

2 MEGAKARYOCYTE HEMATOPOIESIS DEVELOPMENT

Primitive hematopoiesis is the first step in the process of hematopoiesis, which takes place during ontogeny. Researchers have spent a significant amount of time and effort, primarily on mice, investigating hematopoietic development. According to Moore and Metcalf's 1970 research, the first occurrence of hematopoiesis in mice was the formation of structures known as blood islands in the yolk sac. The yolk sac is an extrafetal membrane tissue that surrounds the embryo beginning somewhere around day 7 of the fetal phase. The majority of fetal red blood cells containing fetal hemoglobin are formed in blood islands (Silver & Palis, 1997), but macrophages (Palis et al., 1999) and megakaryocytes (Tober et al., 2007) are also formed. Around day 10 of the fetal phase, definitive hematopoiesis begins with the generation of hematopoietic stem cells (HSCs) from the AGM area in the fetus, with the produced HSCs moving to the liver (Medvinsky & Dzierzak, 1996). On day 16 of the fetal phase, the HSCs begin to continually self-renew and differentiate (Ema & Nakauchi, 2000), developing both themselves and a variety of adult blood cells at the same time. This process is documented in the research of Ema & Nakauchi. The fetal liver is the primary site of hematopoiesis immediately after birth, but HSCs migrate to the bone marrow shortly before birth, where hematopoiesis also occurs, and in adults is the site of hematopoiesis throughout life. Long-term (LT) HSCs may be transplanted into mice with diminished hematopoietic capability (Osawa et al., 1996), whereas short-term (ST) HSCs have pluripotency but only transitory self-renewal ability (Osawa et al., 1996). (Christensen & Weissman, 2001). As the cells progress from stem-like HSCs into multipotent progenitors (MPPs), they lose the capacity to undergo self-renewal throughout this stage of development. In the not too distant future, MPPs will serve as the progenitors of all blood cells. After that, the common lymphoid progenitors (CLP), granulocyte/monocyte progenitors (GMP), megakaryocyte/erythroblast progenitors (MEP), and common myeloid progenitors (CMP) were purified and identified, and the pathways of their hematopoietic differentiation system were clarified (Akashi et al., 2000; Kondo et al., 1997). In accordance with the conventional understanding of megakaryopoiesis, HSCs are capable of differentiating into megakaryocyte progenitors known as MPPs, CMPs, and MEPS after undergoing the process of megakaryopoiesis.

According to research conducted by Bartley et al. and Kaushansky et al. in 1994, thrombopoietin (TPO), which is mostly produced by the liver, is an important cytokine for the development of megakaryocytes. In addition, cytokines such as interleukin (IL)-3 (Teramura et al., 1988), IL-6 (Navarro et al., 1991), IL-11 (Broudy et al., 1995), GM-CSF (Briddell et al., 1991), SCF (Briddell et al., 1991), and LIF (Metcalf et al., 1991) have been found to promote TPO interacts to a single transmembrane receptor called c-MPL, which dimerizes when TPO attaches. After that, the phosphorylation of tyrosine residues on the c-MPL receptor activates the JAK2/STATs pathway, in addition to MAPKs and PI3K/Akt via RAS, which ultimately results in the synthesis of a collection of megakaryocyte differentiation genes (Beer et al., 2008; Drachman et al., 1995; Grozovsky et al., 2015). transcription factors GATA-1 and FLI-1 are engaged in megakaryocyte differentiation (Deveaux et al., 1996; Frontelo et al., 2007; Stachura et al., 2006). These factors are also involved in the modulation of *mpl* gene expression and the differentiation of MEP fractions into erythrocytes and megakaryocytes (Deveaux et al., 1996; Frontelo et al., 2007). During the maturation of megakaryocytes, the FOG1/GATA1 complex, RUNX1, and FLI-1 have been related to the transcriptional regulation of megakaryocyte differentiation (Lordier et al., 2012; Shimizu et al., 2004, 2009; Wang et al., 2002). These findings were published in Lordier et al.

Platelet activity can be modulated by NF-E2, which also contributes to the creation of platelets and enhances the formation of proplatelets in mature megakaryocytes (Levin et al., 1999; Shivdasani et al., 1995). These findings were published in two separate studies. Although the above describes the classic model for the generation of megakaryocytes and platelets, it was recently discovered that HSCs contain megakaryocyte repopulating progenitors (MKrPs) (Yamamoto et al., 2013). This contradicts the model described above. Straight from the HSCs, MKrPs are destined to develop into megakaryocytes in their mature state. In addition, certain HSCs that express von Willebrand factor (vWF), a protein that is present on megakaryocytes, have been demonstrated to develop directly into megakaryocytes (Sanjuan-Pla et al., 2013). This was discovered by the researchers that worked on the study. Additionally, MPPs were divided into four distinct groups (MPP1-4), each of which possessed a unique skew differentiation lineage. According to Pietras et al.'s (2015) research, MPP2 is especially predisposed to megakaryocyte and erythrocyte differentiation. According to Rodriguez-Fraticelli et al. (2018), it has also been discovered that MPP2 can develop into megakaryocytes in a direct manner.

3 BENEFITS OF BLOOD PRODUCTS MADE FROM iPS CELLS

Pluripotent stem cells, also known as iPS cells, have the capacity to self-renew and can proliferate indefinitely when cultured in vitro. Reconstructing the hematopoietic system with iPS cells in order to gain a better understanding of the developmental mechanism could be beneficial. In addition, iPS cells that are produced from specific individuals have the potential to be used for disease modeling, which can aid in the investigation of pathology and the testing of medications. Because of the simplicity with which iPS cells may be genetically changed via CRISPR/Cas9 and other technologies, it is possible to explore the function that particular genes play in the process of development as well as disease. In the field of regenerative medicine, patients' own cells as well as highly immunocompatible iPS cells could serve as potential source cells. iPS cells have been successfully differentiated into several different types of blood cells, including lymphocytes (Nishimura et al., 2013; Themeli et al., 2013; Vizcardo et al., 2013); myeloid cells (Haruta et al., 2013); erythrocytes (Hirose et al., 2013; Kurita et al., 2013); the nonpathogenicity of iPS cell-derived Induced pluripotent stem (iPS) cells may be used to generate a wide variety of blood cell lines, each of which would be capable of both self-replication and cryopreservation. This would result in an enormous number of blood cell lines that are both safe and functional and could be stored in a master cell bank. By adhering to good manufacturing practice or good gene, cellular, and tissue-based products manufacturing practice (GCTP) standards for the manufacturing process after freezing, it would be possible for it to manufacture blood products of an assured clinical grade quality.

4 PLATELET DIFFERENTIATION WITH ES AND iPS CELLS

A single platelet transfusion in Japan consists of 10 units, which is equivalent to around 200 billion platelets. Utilizing the capacity of iPS cells to self-renew indefinitely has allowed us, together with other groups, to devise a method for vastly increasing the quantity of iPS cells used in the production of megakaryocytes and platelets. This method was developed in order to meet the demand for these products. By co-culturing mouse fetal 10T1/2 cells with ES/iPS cells in the presence of vascular endothelial growth factor (VEGF), our differentiation method is able to produce ES/iPS cell-derived sac-like structures. These structures are referred to as ES/iPS-sac. Blood progenitor cells are contained within the sac's interior. According to Takayama et al. (2008) and Takayama et al. (2010), it is possible for these progenitor cells to directly develop into megakaryocytes and platelets if they are grown in the presence of soluble factors such as SCF and TPO.

The acquired platelets are responsible for the formation of thrombi in vivo. Feng et al. were able to develop iPS cells directly into megakaryocytes and platelets by using the EB approach (Feng et al., 2014). This was accomplished in a medium that lacked a feeder, included no serum, and contained no animal components. In addition, they utilized the TALEN technique to generate genetically altered HLA-null iPS cells into megakaryocytes and platelets, revealing that the platelets are capable of performing their intended role. (Hansen et al., 2018) Hansen et al. used a monolayer differentiation system to convert single iPS cells into blood progenitor cells in an environment free of feeder cells and serum.

They subsequently differentiated the blood progenitor cells into megakaryocyte, erythroid, and myeloid cells. None of these methods have been proven to be useful for actual clinical practice since the procedures are so complicated and the incubation times are so long. As a solution to the problems described in the introduction, our team devised an innovative strategy for immortalizing megakaryocytes.

5 The Generation of Immortal Megakaryocyte Cell Lines from Individual Primary Stem Cells

Using our previous ES/iPS cells differentiation approach, we found that the expression of c-MYC is repressed during the maturation phase of megakaryocytes, whereas it is raised during the proliferation phase of megakaryocyte progenitor cells (Takayama et al., 2010). This was something that we observed. As a consequence of this, c-MYC transgenic mice had a greater population of megakaryocytes than wild type mice, although there was no discernible difference in the quantity of platelets (WT; Thompson et al., 1996). On the other hand, c-MYC knockout animals had megakaryocytes with a low ploidy level (8N) and platelets with a high MPV. In addition to this, c-MYC knockout animals had a greater number of megakaryocytes and platelets than wild-type mice did (Guo et al., 2009). According to these findings, it appears that carefully managed expression of c-MYC is necessary for the maturation and proliferation of megakaryocytes. When ES cells were used to create blood progenitors, overexpression of c-MYC led to a temporary increase in megakaryocyte proliferation. However, this was followed by cellular senescence and eventually death. Because the polycomb complex component BMI1 and the BCL2 family member BCL-XL repress the cellular senescence-inducing INK4A/ARF gene locus and apoptosis, we were able to create immortalized megakaryocyte cell lines (imMKCLs) by transferring the c-MYC and BMI1 genes, followed by the BCL-XL gene, into human iPS/ES-derived hematopoietic (Hema) cells (Nakamura et al., 2014). Adding doxycycline leads imMKCLs to proliferate with the expression of the three genes switched on (designated as DOX ON), but removing doxycycline allows imMKCLs to mature and release platelets (designated as DOX OFF). This is due to the fact that these three genes are controlled by the Tet-On system in our system. We proposed a method to produce a large number of clinically applicable platelets from these imMKCL master cells through liquid culture in accordance with good manufacturing practice or GMP clinical grade standards. This would be accomplished by stocking a large quantity of imMKCL strains as a master cell bank and confirming both their safety and their high level of productivity.

The high cost, on the other hand, makes it necessary to find ways to improve the conditions of the cultural media. In the first iteration of the imMKCL medium, we needed to use pricey recombinant proteins such stem cell factor (SCF) and thrombopoietin (TPO). However, we have only recently developed a TPO-like agonist in the form of the small molecule TA-316 (Aihara et al., 2017). KP-457 was found to block a disintegrin and metalloprotease 17 (ADAM17) activity at culture temperatures of 37 degrees Celsius (Hirata et al., 2017). This activity cleaves the extracellular surface of the vWF receptor GPIb (CD42b). KP-457 was discovered under these conditions.

Moreau et al. forced the expression of GATA1, FLI1, and TAL1 during the differentiation of iPS cells into megakaryocytes (Moreau et al., 2016). This resulted in the creation of forward programmed megakaryocytes (fopMKs), which is a cryopreservable and expandable megakaryocyte cell line. Overexpressing NF-E2, Maf-G, and Maf-K in human and mouse fibroblasts was the method that Ono et al. utilized in order to develop megakaryocytic cells. This method did not involve the use of iPS cells. (Ono et al., 2012). (Tozawa et al., 2019) They also produced megakaryocytes from a human adipose-derived mesenchymal stem cell line that proliferated for over two months. These cell lines have the potential to become a useful source of material if the conditions for growth on a big scale are optimized.

SIX NEW PHYSICAL FACTORS IN THE PRODUCTION OF PLATELETS IN VIVO HAVE BEEN DISCOVERED

Feeder cells are necessary for the culture of imMKCL throughout the proliferation and maturation stages (adhesion dependent), however a culture that does not require feeder cells is necessary for therapeutic usage. Throughout the whole growth phase, we were able to cultivate imMKCLs successfully in a 100-ml flask and a 1–20-L WAVE bag system with a moderate rocking motion but without the need of feeder cells. It was revealed that the combination of Rho-associated protein kinase (ROCK) inhibitors and aryl hydrocarbon receptor (AhR) antagonists could permit platelet formation in feeder-free circumstances throughout the maturation phase (Ito et al., 2018). This was reported by Gobbi et al. (2013) and Strassel et al. (2016), respectively.

According to two-photon microscopy (Junt et al., 2007), the cytoplasm extends from megakaryocytes in the bone marrow to the lumen of blood vessels. There, the terminals of the protrusions are split by blood flow stimulation. It is believed that shear stress is the fundamental factor responsible for cytoplasmic cleavage. Shear stress has been used as the foundation for the construction of bioreactors by a number of different organizations, including our own (Avanzi et al., 2016; Di Buduo et al., 2015; Nakagawa et al., 2013). A microfluidic platelet bioreactor that imitated the environment of bone marrow was built by Thon et al. by loading human umbilical vein endothelial cells (HUVECs) and extracellular matrix components onto a chip (Thon et al., 2014). This allowed the researchers to study how platelets behave in the bone marrow. Blin et al. developed a bioreactor that has a number of vWF-coated micropillars that work as megakaryocyte anchors (Blin et al., 2016). This bioreactor efficiently enables shear stress to be applied to megakaryocytes. Since platelet production efficiency was low across the board for the reactors, we made the assumption that shear stress alone does not adequately portray the environment of the bone marrow. As a consequence of this, we decided to further explore the areas in the bone marrow where platelets are manufactured by employing two-photon microscopy and particle image velocimetry (PIV). Platelets were sheared and freed from proplatelets at a bloodstream site that was subjected to turbulence, which indicates that turbulence plays a physical function in the production of platelets as well (Ito et al., 2018).

PLATELET PREPARATIONS MADE FROM iPS CELLS THAT ARE USED IN THE PRODUCTION

On the basis of the findings that turbulence promotes to platelet production *in vivo*, we cultured imMKCLs in a vertical reciprocal motion liquid culture bioreactor (VerMES) with adjustable turbulent physical circumstances. The VerMES has a capacity of 2.4 liters and can produce turbulent physical conditions of varying degrees. Using this technique, we were able to generate iPS cell-derived platelets that functioned very similarly to platelets *in vivo* in a very efficient manner (approximately 80 platelets per megakaryocytes).

An investigation into the effects of varying levels of turbulence on the physical features of culture vessels as well as the formation of platelets was carried out with the use of 0.3-L and 2.4-L VerMES. It was determined that the volume of the VerMES culture vessel has no bearing on the appropriate quantities of shear stress and turbulent energy that should be present. As a consequence of this, we adjusted the shear stress and turbulent energy in an 8-L VerMES in order to generate 100 billion platelets that are functional. Through the use of electron microscopy, it was discovered that the ultrastructures of platelets produced from iPS cells and platelets seen *in vivo* are completely identical. Watanabe et al. (2017) used thrombocytopenic mouse and rabbit models to establish that the iPS cell-derived platelets exhibited a hemostatic capability similar to donor platelets (Ito et al., 2018). This was demonstrated by the fact that the iPS cell-derived platelets were able to clot blood in the same manner as donor platelets.

Since an examination of imMKCLs cultivated in VerMES and static cultures indicated practically no difference in gene expression patterns (Ito et al., 2018), our team came up with the hypothesis that key components that stimulate platelet synthesis may be released from imMKCLs in VerMES cultures. Proteomic examination of the culture supernatant revealed an increase in the secretion of six proteins in the VerMES culture as compared to the culture that was maintained in static conditions. This was determined by examining the difference between the two cultures. It was surprising to find that adding the VerMES culture supernatant to the static culture did not have much of an effect on the creation of platelets. This finding suggests that soluble factors and physical stimuli, including shear stress, work together to stimulate platelet development. Platelet production can be stimulated by sardilysin (NRDC; Nishi, 2013), macrophage migration inhibitory factor (MIF; Strußmann et al., 2013), and insulin-like growth factor binding protein 2 (IGFBP2; Coppé et al., 2008). All three of these factors have been shown to have this effect. In cultures where neither MIF nor IGFBP2 was present, proplatelet generation was shown to be much lower, as determined by observations performed in a microfluidic chip environment. Further investigation found that the absence of MIF and IGFBP2 resulted in a reduction in the amount of extracellular matrix that was secreted, which in turn inhibited proplatelet formation. According to Nishi (2013), NRDC was discovered in a turbulent environment around proplatelets, and it is hypothesized that it plays a role in the endopeptidase-mediated fragmentation of the proplatelets. In conclusion, it is believed that stimulation of turbulent flow prompts the growth of proplatelets by means of an autocrine mechanism. This process ultimately results in shear stress cleaving the cell membrane, which is necessary for the production of platelets.

8 DIFFERENCES IN MEGAKARYOCYTE MATURATION AND PLATELET PRODUCTION BETWEEN IN VITRO AND IN VIVO

Adult megakaryocytes in the bone marrow mature into giant polyploid cells with chromosome numbers ranging from 16N to 124N, migrate into the vascular niche, come into contact with collagen type IV in the vein's basement membrane, and form proplatelet protrusions in order to release platelets into the bloodstream (Semeniak et al., 2016). This process allows platelets to be released into the bloodstream. On the other hand, megakaryocytes generated from iPS cells almost exclusively consist of weakly polyploid cells, with numbers ranging from 2N to 32N. (Takayama et al., 2010). In a similar manner, the number of nucleosomes found in megakaryocytes that were produced in vitro from CD34+ cells isolated from peripheral blood can range anywhere from 2N to 32N. (Liu et al., 2011). The formation of proplatelets begins as protrusions at numerous places along the cell membrane in vitro. These protrusions elongate and release platelets.

It is estimated that a single MK in the bone marrow will generate between 800 and 2,000 platelets, whereas imMKCLs only produce between 60 and 80 platelets per cell. In addition, platelets generated from iPS can be anywhere from 2 to 10 times larger than those generated in vivo, which are just 2 to 4 times larger. After being injected into mice, it was noticed that the large iPS-derived platelets became broken due to the movement of blood (Ito et al., 2018).

It is currently believed that the involvement of the vascular niche and the environment of the bone marrow has not been sufficiently adapted to the growth conditions in vitro. This is due to the fact that the formation of polyploid cells and platelets is significantly lower in vitro than it is in vivo.

COMPATIBILITY OF 9 HLA ANTIGENS WITH iPS CELL-DERIVED PLATELETS

It is possible to become sensitized to non-self HLA-I and generate antibodies against it if one is pregnant or receives a significant number of platelet transfusions. As a direct consequence of this, between 5 and 15 percent of patients who undergo platelet transfusions experience allo-PTR, which is the rejection of transfused platelets due to an incompatibility with HLA-I. Platelets that are compatible with the individual's HLA are necessary for these patients, but they are not always readily available, especially in unusual circumstances or during medical emergencies (Stanworth et al., 2015). Platelets produced from iPS cells offer a number of potential solutions to the problem of allo-PTR. To get started, iPS cells taken from the patient can be used to make autologous platelets (<https://jrct.niph.go.jp/en-latest-detail/jRCTa050190117>). This will get the process off to a good start. This product is completely compatible with nature, including HLA and the human platelet antigen (HPA), which is an alloantigen on platelets that can generate allo-PTR and post-transfusion purpura (Semple et al., 2011; Stanworth et al., 2015). However, the production of autologous platelets for each individual is a time- and resource-intensive process that can be rather expensive.

Alternately, our laboratory along with a number of others have been stockpiling homozygous HLA haplotypes in iPS cells (Turner et al., 2013; Umekage et al., 2019). These cells are highly compatible with one another. The 10 most prevalent lines of induced pluripotent stem cells (iPSCs) that have homozygous HLA have the potential to cover around half of the Japanese population, according to estimations. These cells can be employed as a universal product without the necessity for a library of HLA haplotypes (Feng et al., 2014; Gras et al., 2013; Suzuki et al., 2020). In addition, they can be utilized as a substrate for the production of additional modified products, which may ultimately result in the development of novel platelet therapies.

10 CONSIDERATIONS

Since the announcement that human iPS cells had been developed in 2007, there have been a total of thirteen years pass. It has been demonstrated that adequate quantities of platelets derived from iPS cells can be created for use in therapeutic transfusions. As a direct consequence of this, a first-in-human clinical research utilizing autologous iPSC-derived platelets in patients with allo-PTR was initiated in 2019 (<https://jrct.niph.go.jp/en/latest-detail/jRCTa050190117>). One of the issues that are now being faced is bringing down the price of production. In this context, greater maturation of imMKCLs is necessary by building a culture system that simulates the environment seen in living organisms. In the future, further technological improvements will reach levels that are industrialized, making it possible to construct new medical systems that will make it possible to have safe and ready transfusion systems whenever they are needed.

References

- Aihara, A., Koike, T., Abe, N., Nakamura, S., Sawaguchi, A., Nakamura, T., Sugimoto, N., Nakauchi, H., Nishino, T., & Eto, K. (2017). Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells. *Blood Adv.* 1, 468–476. <https://doi.org/10.1182/bloodadvances.2016000844>
- Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. *Nature*, 404, 193–197. <https://doi.org/10.1038/35004599>
- Abdelhamid, H. N., M. Dowaidar, M. Hällbrink, and Ü. Langel. 2019. “Cell Penetrating Peptides-Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles: An Efficient Gene Delivery Platform.” *SSRN Electron. J.* https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3435895.
- Abdelhamid, Hani Nasser, Moataz Dowaidar, and Ülo Langel. 2020. “Carbonized Chitosan Encapsulated Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles for Gene Delivery.” *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 302 (August): 110200. <https://doi.org/10.1016/j.micromeso.2020.110200>.
- Abdelhamid, Hani Nasser, Moataz Dowaidar, Mattias Hällbrink, and Ülo Langel. 2020. “Gene Delivery Using Cell Penetrating Peptides-Zeolitic Imidazolate Frameworks.” *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 300 (June): 110173. <https://doi.org/10.1016/j.micromeso.2020.110173>.
- Ahmad, Almeman, Khalaf Hassan, Rasool Semaab, Moataz Dowaidar, and Al Orainy Mohammad. 2013. “The Impact of CYP2C19 Polymorphism on Platelet Reactivity for Guiding Clopidogrel Treatment and Cost Analysis.” *Journal of the Saudi Heart Association* 25 (2): 107. <https://doi.org/10.1016/j.jsha.2013.03.005>.
- Algahtasham, Abdullah, Ahmad A. A. Settin, Ahmad Ali, and Hisham Ismail. n.d. “Association of MTHFR C677T and A1298C Polymorphisms with Hypertension among Saudi Subjects from Qassim Region.” *International Journal of Health Sciences* 6 (1). Accessed June 18, 2021. <http://ijhs.org.sa/index.php/journal/article/view/312>.

Alghasham, Abdullah, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2011. "Methylenetetrahydrofolate Reductase (MTHFR) and Angiotensin Converting Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim Region." *International Journal of Health Sciences* 5 (2 Suppl 1): 3–4. <https://www.ncbi.nlm.nih.gov/pubmed/23284552>.

Alghasham, Abdullah, Ahmad A. Settin, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012a. "Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension." *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.

Alghasham, Abdullah, Ahmad Ali, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2012. "CYP2J2 -50 G/T and ADRB2 G46A Gene Polymorphisms in Saudi Subjects with Hypertension." *Genetic Testing and Molecular Biomarkers* 16 (9): 1027–31. <https://doi.org/10.1089/gtmb.2012.0006>.

Ali, Ahmad, Abdullah Alghasham, Hisham Ismail, Moataz Dowaidar, and Ahmad Settin. 2013. "ACE I/D and eNOS E298D Gene Polymorphisms in Saudi Subjects with Hypertension." *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS* 14 (4): 348–53. <https://doi.org/10.1177/1470320312459976>.

Ali, Ahmed A. A., Nahla M. Wassim, Moataz Dowaidar, and Ahmed E. Yaseen. 2013b. "Association of eNOS (E298D) and CYP2J2 (-50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases." *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.

Ali, Ahmed A. A., Nahla M. Wassim, Moataz M. Dowaidar, and Ahmed E. Yaseen. 2013a. "Genetic Polymorphism of CYP2D6 Gene among Egyptian Hypertensive Cases." *The Journal of Basic & Applied Zoology* 66 (4): 228–33. <https://doi.org/10.1016/j.jobaz.2012.12.002>.

Aljarallah, Badr, Ahmed Ali, Moataz Dowaidar, and Ahmad Settin. 2011. "Prevalence of α -1-Antitrypsin Gene Mutations in Saudi Arabia." *Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association* 17 (4): 256–60. <https://doi.org/10.4103/1319-3767.82580>.

Avanzi, M. P., Oluwadara, O. E., Cushing, M. M., Mitchell, M. L., Fischer, S., & Mitchell, W. B. (2016). A novel bioreactor and culture method drives high yields of platelets from stem cells. *Transfusion*, 56, 170–178. <https://doi.org/10.1111/trf.13375>

Bartley, T. D., Bogenberger, J., Hunt, P., Li, Y. S., Lu, H. S., Martin, F., Chang, M. S., Samal, B., Nichol, J. L., Swift, S., Johnson, M. J., Hsu, R.-Y., Parker, V. P., Suggs, S., Skrine, J. D., Merewether, L. A., Clogston, C., Hsu, E., Hokom, M. M., ... Rosselman, R. A. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpI. *Cell*, 77, 1117–1124. [https://doi.org/10.1016/0092-8674\(94\)90450-2](https://doi.org/10.1016/0092-8674(94)90450-2)

Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., Wheatley, K., Buck, G., Harrison, C. N., & Green, A. R. (2008). MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. *Blood*, 112, 141–149. <https://doi.org/10.1182/blood-2008-01-131664>

Blin, A., Le Goff, A., Magniez, A., Poirault-Chassac, S., Teste, B., Sicot, G., Nguyen, K. A., Hamdi, F. S., Reyssat, M., & Baruch, D. (2016). Microfluidic model of the platelet-generating organ: Beyond bone marrow biomimetics. *Sci. Rep.* 22, 21700. <https://doi.org/10.1038/srep21700>

Briddell, R. A., Bruno, E., Cooper, R. J., Brandt, J. E., & Hoffman, R. (1991). Effect of c-kit ligand on in vitro human megakaryocytopoiesis. *Blood*, 78, 2854–2859. <https://doi.org/10.1182/blood.V78.11.2854.2854>

Broudy, V. C., Lin, N. L., & Kaushansky, K. (1995). Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. *Blood*, 85, 1719–1726. <https://doi.org/10.1182/blood.V85.7.1719.bloodjournal8571719>

Christensen, J. L., & Weissman, I. L. (2001). Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells. *PNAS*, 98, 14541–14546. <https://doi.org/10.1073/pnas.261562798>

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science*, 339, 819–823. <https://doi.org/10.1126/science.1231143>

Coppé, J. P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P. Y., & Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* 6, 2853–2868. <https://doi.org/10.1371/journal.pbio.0060301>

Deveaux, S., Filipe, A., Lemarchandel, V., Ghysdael, J., Roméo, P. H., & Mignotte, V. (1996). Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. *Blood*, 87, 4678–4685. <https://doi.org/10.1182/blood.V87.11.4678.bloodjournal87114678>

Di Buduo, C. A., Wray, L. S., Tozzi, L., Malara, A., Chen, Y., Ghezzi, C. E., Smoot, D., Sfara, C., Antonelli, A., Spedden, E., Bruni, G., Staii, C., De Marco, L., Magnani, M., Kaplan, D. L., & Balduini, A. (2015). Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. *Blood*, 125, 2254–2264. <https://doi.org/10.1182/blood-2014-08-595561>

Dowaidar, M., J. Regberg, D. A. Dobchev, and T. Lehto. 2017. “Refinement of a Quantitative Structure–activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems.” *International Journal of*. <https://link.springer.com/content/pdf/10.1007/s10989-016-9542-8.pdf>.

Dowaidar, Moataz, and Ahmad Settin. 2010. “Risk of Myocardial Infarction Related to Factor V Leiden Mutation: A Meta-Analysis.” *Genetic Testing and Molecular Biomarkers* 14 (4): 493–98. <https://doi.org/10.1089/gtmb.2010.0017>.

Dowaidar, Moataz, and Moataz Dowaidar. 2018. “Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis.”

Dowaidar, Moataz, H. A. Ismail, A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. “Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region.” *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.

Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Krista Freimann, Kaido Kurrikoff, Xiaodong Zou, and Ülo Langel. 2017. “Magnetic Nanoparticle Assisted Self-Assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery.” *Scientific Reports* 7 (1): 9159. <https://doi.org/10.1038/s41598-017-09803-z>.

Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. “Supplemental Material for Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles–cell-Penetrating Peptide.” *SAGE Journals*. <https://doi.org/10.25384/SAGE.7105436.V1>.

Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. “Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles-Cell-Penetrating Peptide.” *Journal of Biomaterials Applications* 33 (3): 392–401. <https://doi.org/10.1177/0885328218796623>.

Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Xiaodong Zou, and Ülo Langel. 2017a. “Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery General Subjects.” *Biochimica et Biophysica Acta, General Subjects*. <https://pubag.nal.usda.gov/catalog/5734174>.

Dowaidar, Moataz. 2017. “In-Silico Design of Peptide-Based Transfection Systems, in-Vitro Validation, and up-Take Pathways Investigation.” *Department of Neurochemistry, Stockholm University*.

Drachman, J. G., Griffin, J. D., & Kaushansky, K. (1995). The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. *J. Biol. Chem.* 87, 2162–2170. <https://doi.org/10.1074/jbc.270.10.4979> Google Scholar

Ema, H., & Nakauchi, H. (2000). Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. *Blood*, 95, 2284–2288. <https://doi.org/10.1182/blood.V95.7.2284>

Estcourt, L. J., Birchall, J., Allard, S., Bassey, S. J., Hersey, P., Kerr, J. P., Mumford, A. D., Stanworth, S. J., & Tinegate, H. (2017). Guidelines for the use of platelet transfusions. *Br. J. Haematol.* 176, 365–394. <https://doi.org/10.1111/bjh.14423> Wiley Online Library PubMed Web of Science@Google Scholar

Feng, Q., Shabrani, N., Thon, J. N., Huo, H., Thiel, A., Machlus, K. R., Kim, K., Brooks, J., Li, F., Luo, C., Kimbrel, E. A., Wang, J., Kim, K.-S., Italiano, J., Cho, J., Lu, S.-J., & Lanza, R. (2014). Scalable generation of universal platelets from human induced pluripotent stem cells. *Stem Cell Rep.* 3, 817–831. <https://doi.org/10.1016/j.stemcr.2014.09.010>

Frontelo, P., Manwani, D., Galdass, M., Karsunky, H., Lohmann, F., Gallagher, P. G., & Bieker, J. J. (2007). Novel role for EKLF in megakaryocyte lineage commitment. *Blood*, 110, 3871– 3880. <https://doi.org/10.1182/blood-2007-03-082065>

Gestin, Maxime, Moataz Dowaidar, and Ülo Langel. 2017. “Uptake Mechanism of Cell-Penetrating Peptides.” *Advances in Experimental Medicine and Biology* 1030: 255–64. https://doi.org/10.1007/978-3-319-66095-0_11.

Gobbi, G., Mirandola, P., Carubbi, C., Masselli, E., Sykes, S. M., Ferraro, F., Nouvenne, A., Thon, J. N., Italiano, J. E., & Vitale, M. (2013). Proplatelet generation in the mouse requires PKC ϵ -dependent RhoA inhibition. *Blood*, 122, 1305– 1311.

Gras, C., Schulze, K., Goudeva, L., Guzman, C. A., Blasczyk, R., & Figueiredo, C. (2013). HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. *Hum. Gene Ther.* 24, 1018– 1028. <https://doi.org/10.1089/hum.2013.074>

Grozovsky, R., Begonja, A. J., Liu, K., Visner, G., Hartwig, J. H., Falet, H., & Hoffmeister, K. M. (2015). The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. *Nat. Med.* 21, 47– 54. <https://doi.org/10.1038/nm.3770>

Guo, Y., Niu, C., Breslin, P., Tang, M., Zhang, S., Wei, W., Kini, A. R., Paner, G. P., Alkan, S., Morris, S. W., Diaz, M., Stiff, P. J., & Zhang, J. (2009). c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. *Blood*, 114, 2097– 2106. <https://doi.org/10.1182/blood-2009-01-197947>

Hansen, M., Varga, E., Aarts, C., Wust, T., Kuijpers, T., von Lindern, M., & van den Akker, E. (2018). Efficient production of erythroid, megakaryocytic and myeloid cells, using single cell-derived iPSC colony differentiation. *Stem Cell Res.* 29, 232– 244. <https://doi.org/10.1016/j.scr.2018.04.016>

Haruta, M., Tomita, Y., Yuno, A., Matsumura, K., Ikeda, T., Takamatsu, K., Haga, E., Koba, C., Nishimura, Y., & Senju, S. (2013). TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. *Gene Ther.* 20, 504– 513. <https://doi.org/10.1038/gt.2012.59>

Hirata, S., Murata, T., Suzuki, D., Nakamura, S., Jono-Ohnishi, R., Hirose, H., Sawaguchi, A., Nishimura, S., Sugimoto, N., & Eto, K. (2017). Selective inhibition of ADAM17 efficiently mediates glycoprotein Ib α retention during ex vivo generation of human induced pluripotent stem cell-derived platelets. *Stem Cells Transl. Med.* 6, 720– 730. <https://doi.org/10.5966/sctm.2016-0104>

Hirose, S.-I., Takayama, N., Nakamura, S., Nagasawa, K., Ochi, K., Hirata, S., Yamazaki, S., Yamaguchi, T., Otsu, M., Sano, S., Takahashi, N., Sawaguchi, A., Ito, M., Kato, T., Nakauchi, H., & Eto, K. (2013). Immortalization of erythroblasts by c-MYC and BCL-XL enables large-scale erythrocyte production from human pluripotent stem cells. *Stem Cell Rep.* 1, 499– 508. <https://doi.org/10.1016/j.stemcr.2013.10.010>

Ismail, H. A., A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. “Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region.” *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejmb.v29i1.67382>.

Ito, Y., Nakamura, S., Sugimoto, N., Shigemori, T., Kato, Y., Ohno, M., Sakuma, S., Ito, K., Kumon, H., Hirose, H., Okamoto, H., Nogawa, M., Iwasaki, M., Kihara, S., Fujio, K., Matsumoto, T., Higashi, N., Hashimoto, K., Sawaguchi, A., ... Eto, K. (2018). Turbulence activates platelet biogenesis to enable clinical scale ex vivo production. *Cell*, 174, 636– 648.

Junt, T., Schulze, H., Chen, Z., Massberg, S., Goerge, T., Krueger, A., Wagner, D. D., Graf, T., Italiano, J. E., Shivdasani, R. A., & von Andrian, U. H. (2007). Dynamic visualization of thrombopoiesis within bone marrow. *Science*, 317, 1767– 1770.

Kaushansky, K., Lok, S. I., Holly, R. D., Broudy, V. C., Lin, N., Bailey, M. C., Forstrom, J. W., Buddle, M. M., Oort, P. J., Hagen, F. S., Roth, G. J., Papayannopoulou, T., & Foster, D. C. (1994). Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. *Nature*, 369, 568– 571. <https://doi.org/10.1038/369568a0>

Kondo, M., Weissman, I. L., & Akashi, K. (1997). Identification of clonogenic common lymphoid progenitors in mouse bone marrow. *Cell*, 91, 661–672. [https://doi.org/10.1016/S0092-8674\(00\)80453-5](https://doi.org/10.1016/S0092-8674(00)80453-5)

Kosaki, G. (2008). Platelet production by megakaryocytes: Protoplatelet theory justifies cytoplasmic fragmentation model. *Int. J. Hematol.* 88, 255–267. <https://doi.org/10.1007/s12185-008-0147-7>

Kurita, R., Suda, N., Sudo, K., Miharada, K., Hiroshima, T., Miyoshi, H., Tani, K., & Nakamura, Y. (2013). Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. *PLoS One*, 8, e59890. <https://doi.org/10.1371/journal.pone.0059890>

Lefrançois, E., Ortiz-Muñoz, G., Caudrillier, A., Mallavia, B., Liu, F., Sayah, D. M., Thornton, E. E., Headley, M. B., David, T., Coughlin, S. R., Krummel, M. F., Leavitt, A. D., Passequé, E., & Looney, M. R. (2017). The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature*, 544, 105–109. <https://doi.org/10.1038/nature21706>

Levin, J., Peng, J. P., Baker, G. R., Villeval, J. L., Lecine, P., Burstein, S. A., & Shivdasani, R. A. (1999). Pathophysiology of thrombocytopenia and anemia in mice lacking transcription factor NF-E2. *Blood*, 94, 3037–3047. <https://doi.org/10.1182/blood.V94.9.3037>

Liu, Z. J., Italiano, J., Ferrer-Marin, F., Gutti, R., Bailey, M., Poterjoy, B., Rimsza, L., & Sola-Visner, M. (2011). Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. *Blood*, 117, 4106–4117. <https://doi.org/10.1182/blood-2010-07-293092>

Lordier, L., Bluteau, D., Jalil, A., Legrand, C., Pan, J., Rameau, P., Jouni, D., Bluteau, O., Mercher, T., Leon, C., Gachet, C., Debili, N., Vainchenker, W., Raslova, H., & Chang, Y. (2012). RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. *Nat. Comm.* 3, 717. <https://doi.org/10.1038/ncomms1704>

Machlus, K. R., & Italiano, J. E. (2013). The incredible journey: From megakaryocyte development to platelet formation. *J. Cell Biol.* 201, 785–796. <https://doi.org/10.1083/jcb.201304054>

Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. *Science*, 339, 823–826.

Medvinsky, A., & Dzierzak, E. (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell*, 86, 897–906. [https://doi.org/10.1016/S0092-8674\(00\)80165-8](https://doi.org/10.1016/S0092-8674(00)80165-8)

Metcalf, D., Hilton, D., & Nicola, N. (1991). Leukemia inhibitory factor can potentiate murine megakaryocyte production in vitro. *Blood*, 77, 2150–2153. <https://doi.org/10.1182/blood.V77.10.2150.2150>

Abdelhamid, H. N., M. Dowaidar, M. Hällbrink, and Ü. Langel. 2019. Cell Penetrating Peptides-Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles: An Efficient Gene Delivery Platform. *SSRN Electron. J.* https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3435895.

Abdelhamid, Hani Nasser, Moataz Dowaidar, Mattias Hällbrink, and Ülo Langel. 2020. Gene Delivery Using Cell Penetrating Peptides-Zeolitic Imidazolate Frameworks. *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 300 (June): 110173. <https://doi.org/10.1016/j.micromeso.2020.110173>.

Abdelhamid, Hani Nasser, Moataz Dowaidar, and Ülo Langel. 2020. Carbonized Chitosan Encapsulated Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles for Gene Delivery. *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 302 (August): 110200. <https://doi.org/10.1016/j.micromeso.2020.110200>.

Ahmad, Almeman, Khalaf Hassan, Rasool Semaab, Moataz Dowaidar, and Al Orainy Mohammad. 2013. The Impact of CYP2C19 Polymorphism on Platelet Reactivity for Guiding Clopidogrel Treatment and Cost Analysis. *Journal of the Saudi Heart Association* 25 (2): 107. <https://doi.org/10.1016/j.jsha.2013.03.005>.

- Alghasham, Abdullah, Ahmad A. A. Settin, Ahmad Ali, and Hisham Ismail. n.d. Association of MTHFR C677T and A1298C Polymorphisms with Hypertension among Saudi Subjects from Qassim Region. *International Journal of Health Sciences* 6 (1). Accessed June 18, 2021. <http://ijhs.org.sa/index.php/journal/article/view/312>.
- Alghasham, Abdullah, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2011. Methylenetetrahydrofolate Reductase (MTHFR) and Angiotensin Converting Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim Region. *International Journal of Health Sciences* 5 (2 Suppl 1): 3–4. <https://www.ncbi.nlm.nih.gov/pubmed/23284552>.
- Alghasham, Abdullah, Ahmad Ali, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2012. CYP2J2 -50 G/T and ADRB2 G46A Gene Polymorphisms in Saudi Subjects with Hypertension. *Genetic Testing and Molecular Biomarkers* 16 (9): 1027–31. <https://doi.org/10.1089/gtmb.2012.0006>.
- Alghasham, Abdullah, Ahmad A. Settin, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012a. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
- Moataz Dowaidar. 2012b. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
- Ali, Ahmad, Abdullah Alghasham, Hisham Ismail, Moataz Dowaidar, and Ahmad Settin. 2013. ACE I/D and eNOS E298D Gene Polymorphisms in Saudi Subjects with Hypertension. *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS* 14 (4): 348–53. <https://doi.org/10.1177/1470320312459976>.
- Ali, Ahmed A. A., Nahla M. Wassim, Moataz M. Dowaidar, and Ahmed E. Yaseen. 2013. Genetic Polymorphism of CYP2D6 Gene among Egyptian Hypertensive Cases. *The Journal of Basic & Applied Zoology* 66 (4): 228–33. <https://doi.org/10.1016/j.jobaz.2012.12.002>.
- Ali, Ahmed A. A., Nahla M. Wassim, Moataz Dowaidar, and Ahmed E. Yaseen. 2013b. Association of eNOS (E298D) and CYP2J2 (-50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases. *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
- Moataz Dowaidar. 2013. Association of eNOS (E298D) and CYP2J2 (-50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases. *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
- Aljarallah, Badr, Ahmed Ali, Moataz Dowaidar, and Ahmad Settin. 2011. Prevalence of α -1-Antitrypsin Gene Mutations in Saudi Arabia. *Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association* 17 (4): 256–60. <https://doi.org/10.4103/1319-3767.82580>.
- Dowaidar, M., J. Regberg, D. A. Dobchev, and T. Lehto. 2017. Refinement of a Quantitative Structure–activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems. *International Journal of*. <https://link.springer.com/content/pdf/10.1007/s10989-016-9542-8.pdf>.
- Dowaidar, Moataz. 2017. In-Silico Design of Peptide-Based Transfection Systems, in-Vitro Validation, and up-Take Pathways Investigation. Department of Neurochemistry, Stockholm University.
- Moataz Dowaidar. 2018. Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis. Department of Biochemistry and Biophysics, Stockholm University. <https://www.diva-portal.org/smash/record.jsf?pid=diva2:1242000>.
- Moataz Dowaidar. Cardiometabolic Conditions Could Be Related to Vitamin D Deficiency. The Genetic Determinants That Affect Vitamin D Pathways May Be Solved with Nanomedicines. <https://doi.org/10.31219/osf.io/nqewr>.
- Moataz Dowaidar. Different Insulin Resistance and Inflammation Pathways Are Influenced by Genetic Factors in Metabolic Syndrome. Gene Therapy Enables Early Recognition and Treatment of the Genetic Factors. <https://doi.org/10.31219/osf.io/gqwj2>.
- Moataz Dowaidar. Gene Therapy Has Been Shown to Be Valuable for Understanding Complex Disease Pathophysiologies. The Medical Profession as a Whole Will Have to Invest in Specialized Investigations. <https://doi.org/10.31219/osf.io/8fg9y>.
- Moataz Dowaidar. Genetic and Epigenetic Discoveries Hold Promising Avenues in Cardiovascular Prevention and Management (CVDs). Key Nucleic Acids Are Being Researched and Developed for Medicinal Use. <https://doi.org/10.31219/osf.io/hk7pe>.
- Moataz Dowaidar. Genome Editing Can Now Be Carried out in an Isogenic Setting. It Can Be Effectively Transmitted to Somatic Tissues in Mice, but Not to Humans. Despite These Doubts, CRIS Has Great Potential as a Medical Promise. <https://doi.org/10.31219/osf.io/4m3v>.

- Moataz Dowaidar. Genome-Wide Association Experiments Have Uncovered a Slew of Cardiometabolic Trait-Associated Variants. This Information Can Be Useful in the Implementation of New Diagnostic and Treatment Strategies. <https://doi.org/10.31219/osf.io/4vws8>.
- Moataz Dowaidar. Genome-Wide Association Studies (GWAS) Have Revolutionized Our View of Human Health and Disease Genetics and Offered Novel Gene Therapy Targets. <https://doi.org/10.31219/osf.io/rvm3z>.
- Moataz Dowaidar. Metabolic Syndrome_ the Presence of Inflammatory Mechanisms in Abdominal Obesity Is Undeniable, Gene Therapy Using Nanoparticles and Adenoviruses Technologies Is Promising. <https://doi.org/10.31219/osf.io/2j5xt>.
- Moataz Dowaidar. miRNAs May Be Used as Preventive Agents for Metabolic Diseases in the near Future. Understanding the Interplay between pro-Adipogenic_ and Anti-Ad Pipogenic miRNA' Could Lead to New Biomarkers. <https://doi.org/10.31219/osf.io/3dr8c>.
- Moataz Dowaidar. Nanomedicine Has Elegantly Attempted to Cure Multiple Gene Polymorphisms and Mutations in Cardiovascular Diseases Using Gene Therapy Techniques. <https://doi.org/10.31219/osf.io/d3x8g>.
- Moataz Dowaidar. Thrombosis Pathways and Therapeutic Strategies. <https://doi.org/10.31219/osf.io/57vyz>.
- Moataz Dowaidar. What Genomic Research Has Told Us about the Obesity and Its Possible Gene Therapy Targets. <https://doi.org/10.31219/osf.io/ym49s>.
- Moataz Dowaidar. Exosomes Can Make the Use of Circulating miRNA as a Biomarker More Feasible. The Aim of Gene Therapy Should Be to Learn Everything There Is to Know about miRNA Activity. <https://doi.org/10.31219/osf.io/edkua>.
- Moataz Dowaidar. Anti-Sense Pathways Have Been Generated Using siRNA. The Liver and Other Often Used Organs Will Now Be Targeted. <https://doi.org/10.31219/osf.io/m6xvp>.
- Moataz Dowaidar. CrisPR/CRIS Systems Are Highly Effective and Useful for Genomic Manipulation. Despite This, Cardiac Treatment Remains Difficult due to Existing Genome Editing and Delivery Processes. <https://doi.org/10.31219/osf.io/3nwzd>.
- Moataz Dowaidar. Discoveries in Gene-Environment Interactions That Influence CVD, Lipid Traits, Obesity, Diabetes, and Hypertension Appear to Be Able to Influence Gene Therapy. <https://doi.org/10.31219/osf.io/cr5af>.
- Moataz Dowaidar. Genome Editing's Potential Target Diseases in the Cardiovascular Field. <https://doi.org/10.31219/osf.io/gc23p>.
- Moataz Dowaidar. Key Genetic Factors in the Metabolic Syndrome Predisposition Which May Be a Therapeutic Options by Gene Therapy. <https://doi.org/10.31219/osf.io/f38sk>.
- Moataz Dowaidar. miRNA Can Be a Part of Both the Onset and Cure of Coronary Heart Disease. <https://doi.org/10.31219/osf.io/teqh8>.
- Moataz Dowaidar. Preclinical Studies and Clinical Trials Have Sparked Interest in Certain Biological Medications for Atherosclerotic Coronary Heart Disease. <https://doi.org/10.31219/osf.io/ts8mh>.
- Moataz Dowaidar. Researchers Would Be Able to Develop a Detailed Picture of Chromatin in Disease, Which Would Be Useful for Gene Therapy. <https://doi.org/10.31219/osf.io/m9z48>.
- Moataz Dowaidar. The Cardiometabolic-Based Chronic Disease Model Lays the Foundations for Accurate, Evidence-Based Preventive Targeting and Gene Therapy. <https://doi.org/10.31219/osf.io/up9z4>.
- Moataz Dowaidar. 2D MOFs Have Unique Features for Biological Applications. They Can Be Utilized for Gene Therapy, Bioimaging, Biosensing, Photodynamic Therapy, and Tissue Engineering. <https://doi.org/10.31219/osf.io/4q9ct>.
- Moataz Dowaidar. 3D Bioprinting for Enhanced Vascularization, and Gene Editing to Provide a More Favorable Immunological Response Are Just Some of the Potential Uses of Carbon Materials. <https://doi.org/10.31219/osf.io/v2xy8>.
- Moataz Dowaidar. Anderson–Fabry Disease Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/tcgka>.
- Moataz Dowaidar. Antisense Oligonucleotides (ASOs) and CRISPR Systems Are Promising Gene Therapy Treatments for Alzheimer's Disease. <https://doi.org/10.31219/osf.io/ws796>.
- Moataz Dowaidar. Any Alteration in PPAR Genomic Sequence, Splicing Pattern, or PTM Is Likely to Cause Major Alterations in Its Function. In Personalized Medicine, Such Data Becomes More Significant in Gene Therapy Design. <https://doi.org/10.31219/osf.io/y8n79>.
- Moataz Dowaidar. Applying Genome-Wide Association Technology to Brain Diseases Enables the Discovery of lncRNAs Targets for Gene Therapy. <https://doi.org/10.31219/osf.io/hm4eu>.
- Moataz Dowaidar. Autophagy and Proteostasis Adjustment Role in Normal Brain Function and Neurodegenerative Disorders. <https://doi.org/10.31219/osf.io/m4yra>.

Moataz Dowaidar. Basal Ganglia-Cerebellar and Brainstem-Cerebellar Circuits May Interact Improperly with Dystonia. Linking Network Disruptions to Cell Failure Will Enable Understanding Pathophysiology and Designing Gene Therapy Methods. <https://doi.org/10.31219/osf.io/8w35s>.

Moataz Dowaidar. Blood Products Are Used to Treat a Multitude of Diseases, so the Blood Transfusion System Needs to Be Enhanced. CRISPR/Cas9 Has Made It Viable to Make HLA Class I-Deleted Blood Products to Avoid Rejection. <https://doi.org/10.31219/osf.io/egr3n>.

Moataz Dowaidar. Calixarenes (CAs) Are Promising in Biomedicine, Biosensing, Bioimaging and Gene Delivery Systems. <https://doi.org/10.31219/osf.io/n9vjy>.

Moataz Dowaidar. CAR T Cell Research Has Quickly Advanced from the Bench to the Clinic and Back. The Results of the Trials Have Revealed New Mechanisms. <https://doi.org/10.31219/osf.io/f9wm7>.

Moataz Dowaidar. CAR T-Cell Treatment Remains Clinically Challenging. Therapeutic Strategies May Be Designed to Cut off Immunotherapy Utilizing Safety Switches. <https://doi.org/10.31219/osf.io/s7x4y>.

Moataz Dowaidar. Central Nervous System Gene Therapy Has Entered a New Development Paradigm. New Techniques Are Being Employed for a Wide Range of Illness Indications and Pathways. <https://doi.org/10.31219/osf.io/j49wz>.

Moataz Dowaidar. Chronic Obstructive Pulmonary Condition (COPD) Is a Prevalent, Preventable, and Curable Illness with Persistent Respiratory Symptoms and Airflow Limitation. <https://doi.org/10.31219/osf.io/vkdut>.

Moataz Dowaidar. CircRNAs Have the Potential to Aid in the Diagnosis and Treatment of Lipid Diseases. <https://doi.org/10.31219/osf.io/y3hp4>.

Moataz Dowaidar. Clinical Symptoms, Underlying Pathogenesis, and the Prospect of Tailored Therapies Have All Benefited from Genetic Discoveries in Parkinson's Disease. <https://doi.org/10.31219/osf.io/pdzqb>.

Moataz Dowaidar. Code Distribution of siRNA for Cancer Genes such as p53 and Bcl2 Family Genes Has Demonstrated Efficacy in Killing Cancer Cells. Nanoparticles Can Produce a Surface Where Numerous Drugs May Be Coupled, Allowing Combinatory Treatment. <https://doi.org/10.31219/osf.io/hvcse>.

Moataz Dowaidar. Cognitive Deficiencies Pathophysiology Are Mainly an Unknown Area. Curing the Neurological Conditions Could Be an Objective for Gene Therapy. <https://doi.org/10.31219/osf.io/23xf8>.

Moataz Dowaidar. CRISPR-Based Gene Editing Is Presently Being Tried in Many Clinical Trials. <https://doi.org/10.31219/osf.io/qbngx>.

Moataz Dowaidar. CRISPR-Cas9 Gene Editing as a Tool for Developing Immunotherapy for Cancer. <https://doi.org/10.31219/osf.io/dvr4t>.

Moataz Dowaidar. CRISPR/Cas System Research Has Advanced Significantly in Biological sciences. There Are Still Many Challenges to Effective Delivery before Efficient Gene Editing May Be Achieved. <https://doi.org/10.31219/osf.io/mc26v>.

Moataz Dowaidar. CRISPR/Cas9 Genome Editing Technology Applications in Biological and Biomedical Fields. <https://doi.org/10.31219/osf.io/ctqbe>.

Moataz Dowaidar. Critical Limb Ischemia Potential Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/aqcpt>.

Moataz Dowaidar. Deep Learning Algorithms for scRNAseq Analysis Have Yielded Positive Results, but There Are Still More Promising Ways That Need to Be Developed for Regenerative Medicine. <https://doi.org/10.31219/osf.io/dh2pt>.

Moataz Dowaidar. Depression May Be Epigenetically Controlled by miRNAs Making It a Diagnostic or Gene Therapy Target. <https://doi.org/10.31219/osf.io/fw65m>.

Moataz Dowaidar. Dermatophytes: Role of Host Genetics in the Development of Illness. <https://doi.org/10.31219/osf.io/mf3bu>.

Moataz Dowaidar. Developments in Biomedical Technology Will Increase the Importance of mRNA in Treating Brain Tumors, as Well as Other Malignancies. <https://doi.org/10.31219/osf.io/tvj5x>.

Moataz Dowaidar. Downstream Processing of Virus, Virus-like Particles and Nanoparticulate Inclusion Bodies to Be Used as Gene Delivery Vehicles for Human Gene Therapy Applications. <https://doi.org/10.31219/osf.io/exa3q>.

Moataz Dowaidar. Dravet Syndrome Is a Severe Developmental and Epileptic Encephalopathy. Fenfluramine and Gene Therapy Are Promising. <https://doi.org/10.31219/osf.io/zvq8y>.

Moataz Dowaidar. Exosomes' Function in Cardiovascular Protection and Neovascularization Implies That They Might Be Used to Treat Ischemia and Atherosclerotic Cardiovascular Diseases. <https://doi.org/10.31219/osf.io/2h8c7>.

- Moataz Dowaidar. Ferroposis Cell Death Can Cause Complications That May Be Difficult to Detect and Quantify: Autophagy Role and Possible Therapeutics. <https://doi.org/10.31219/osf.io/zd2jg>.
- Moataz Dowaidar. Following the Discovery of Anti-MDA5 Ab, the Clinical Understanding of Dermatomyositis Has Been Improved. <https://doi.org/10.31219/osf.io/j2t5f>.
- Moataz Dowaidar. For the Treatment of Cystic Fibrosis, RNA Medicines, Gene Transfer Therapies, and Gene Editing Treatments Have Potential. <https://doi.org/10.31219/osf.io/6afzm>.
- Moataz Dowaidar. Frontotemporal Dementia Is a Complex Disorder with a Wide Spectrum of Clinical Symptoms. Personalized Medicine and Gene Therapy Are Promising Strategies for Treatment. <https://doi.org/10.31219/osf.io/gh4x7>.
- Moataz Dowaidar. G6PD Deficiency Is a Common Genetic Trait That Can Protect Heterozygotes from Dying from Malaria. <https://doi.org/10.31219/osf.io/g2kza>.
- Moataz Dowaidar. Gastric Cancer Is the World's Second-Largest Death Cause. Peptides Can Be Used to Deliver Radiation or Other Fatal Chemicals to Tumors. <https://doi.org/10.31219/osf.io/eu5mj>.
- Moataz Dowaidar. Gene Doping May Be Possible for Lifestyle Enhancement. <https://doi.org/10.31219/osf.io/8xkm5>.
- Moataz Dowaidar. Gene Expression Assays Gather Evidence That They Can Provide Useful Therapeutic Information in Young Women. <https://doi.org/10.31219/osf.io/d372s>.
- Moataz Dowaidar. Gene Therapy and Genome-Editing Treatments That Can Protect Patients from Coronary Artery Disease Are under Investigation. <https://doi.org/10.31219/osf.io/xqgf8>.
- Moataz Dowaidar. Gene Therapy Approaches for Hemophilia A and B. <https://doi.org/10.31219/osf.io/ufc4g>.
- Moataz Dowaidar. Gene Therapy for the Central Nervous System Has Been Initiated. This Expansion Will Require Some Degree of Simplicity in Delivery Processes. <https://doi.org/10.31219/osf.io/hdy5q>.
- Moataz Dowaidar. Gene Therapy for the Treatment of Spinal Muscular Atrophy. <https://doi.org/10.31219/osf.io/kpz5f>.
- Moataz Dowaidar. Gene Therapy May Benefit Inherited Ichthyoses with Concurrent Fungal Infections and Severe Ich Thyroidoses. <https://doi.org/10.31219/osf.io/zxmun>.
- Moataz Dowaidar. Gene Therapy May Target APOE for Alzheimer's Disease. <https://doi.org/10.31219/osf.io/3y52k>.
- Moataz Dowaidar. Gene Therapy Promises Accurate, Targeted Administration and Overcoming Drug Resistance in Diverse Cancer Cells. <https://doi.org/10.31219/osf.io/j34n6>.
- Moataz Dowaidar. Gene Therapy Targeting FVIII, FIX for Haemophilia Treatment. <https://doi.org/10.31219/osf.io/qcbwp>.
- Moataz Dowaidar. Gene Therapy Targeting PRMT5 May Be Useful in Immunotherapy. <https://doi.org/10.31219/osf.io/gkw8j>.
- Moataz Dowaidar. Gene Therapy Using Extracellular Vesicles Loaded with miRNA Derived from Bone Marrow Mesenchymal Stem Cells Is a Cell-Free Medication Delivery Method Used in a Variety of Diseases. <https://doi.org/10.31219/osf.io/3znvz>.
- Moataz Dowaidar. Genetic Engineered MSCs Are Attractive Possibilities for Regenerative Stem-Cell Therapy to Treat Several Liver Diseases. <https://doi.org/10.31219/osf.io/4cfrd>.
- Moataz Dowaidar. Genetic Variants Shared between Alzheimer's Disease and Parkinson's Disease Have Been Discovered in Blood and Brain Samples. Somatic Mosaicism Might Function as an Accelerator. <https://doi.org/10.31219/osf.io/tr58n>.
- Moataz Dowaidar. Genome-Wide Association Studies Promise to Discover Novel Indicators of Hypertension. Endothelin-Related SNPs Are Currently in Clinical Trials. <https://doi.org/10.31219/osf.io/2n4wa>.
- Moataz Dowaidar. Gingival and Intraventricular Haemorrhages Are Severe Newborn Diseases Causing Damage to White Matter and Neurological Dysfunction in Surviving Newborns Who Can Benefit from Gene Therapy. <https://doi.org/10.31219/osf.io/qb84p>.
- Moataz Dowaidar. Glioblastoma Therapeutic Approaches Were Established Utilizing Contemporary Discoveries in Delivering Medicines to the Brain as Smart Nanoparticles for Focused Therapy. <https://doi.org/10.31219/osf.io/db4f6>.
- Moataz Dowaidar. Haemophilia Gene Therapy Is in Clinical Studies, Making Continuous Safety and Efficacy Testing a Key Emphasis. <https://doi.org/10.31219/osf.io/sa8ny>.
- Moataz Dowaidar. Hematopoietic Stem Cell Transplantation and Gene Therapy Are the Sole Treatments for Sickle Cell Disease and Other Hemoglobinopathies. <https://doi.org/10.31219/osf.io/v8xqc>.

Moataz Dowaidar. Huntington's Disease Gene Therapy and Nanomedicines May Be Available Shortly. <https://doi.org/10.31219/osf.io/rxvvd>.

Moataz Dowaidar. Hybrid Gene Therapy Designed to Fully Understand the Underlying Molecular Cancer Process May Be a Feasible Option. <https://doi.org/10.31219/osf.io/ajyfd>.

Moataz Dowaidar. Hydrogels Are Promising Considering Their Incredible Capacity to Modify, Encapsulate and Co-Deliver Medicinal Compounds, Cells, Biomolecules, and Nanomaterials. <https://doi.org/10.31219/osf.io/px3qy>.

Moataz Dowaidar. Immune Evasion Is Linked to Histone Variation Malfunction. Gene Therapy Could Provide Tools for Targeting Histone Variant Deposition as a Critical Part of Its Pharmacology. <https://doi.org/10.31219/osf.io/kjm76>.

Moataz Dowaidar. Implementing the Human Artificial Chromosome Gene Therapy Platform Remains Challenging, but Continuous Animal Model Research Will Advance the Platform Closer to Clinical Trials. <https://doi.org/10.31219/osf.io/a53f7>.

Moataz Dowaidar. Inflammatory Breast Cancer Remains the Most Aggressive Form of Breast Cancer. A Multimodality Therapeutic Plan Has Shown Improved Survival Results. <https://doi.org/10.31219/osf.io/cr935>.

Moataz Dowaidar. Inherited Immunohematological and Metabolic Diseases Have the Potential to Improve Significantly, or Be Cured, Using Haematopoietic Stem Cell Transplantation Gene Therapy. <https://doi.org/10.31219/osf.io/ukbnm>.

Moataz Dowaidar. Insulin and IGF-1 Receptors Mutations Can Lead to Targets for Gene Therapy in Diabetes, Obesity, and Metabolic Syndrome. <https://doi.org/10.31219/osf.io/s86x5>.

Moataz Dowaidar. Integrating High-Throughput Genetics and Neuroimaging Technologies Promises Greater Information on Neurobiological Anomalies in Neurodegenerative Diseases. <https://doi.org/10.31219/osf.io/hpgyz>.

Moataz Dowaidar. Intravitreal and Subretinal Injections Currently Deliver Most Gene Therapy, Including siRNA for Eye Illnesses. Non-Viral Vectors May Provide Targeting. <https://doi.org/10.31219/osf.io/rjkyh>.

Moataz Dowaidar. LncRNA Regulating Reprogramming Glucose Metabolism Has Become One of the Most Tempting Antineoplastic Targets for Gene Therapy. <https://doi.org/10.31219/osf.io/hqma5>.

Moataz Dowaidar. lncRNAs Are Upregulated and Downregulated in OS Cells. Angiogenesis, Metastasis, Cell Signaling, Autophagy, and Death Are among Biological Processes That RNAs Play a Role in. <https://doi.org/10.31219/osf.io/48n7q>.

Moataz Dowaidar. Magnetic Nanoparticles Are Widely Used in Drug Delivery, Imaging, Diagnosis, and Targeting. It Has Promises for the Treatment of Inflammatory Disorders such as Rheumatoid Arthritis. <https://doi.org/10.31219/osf.io/p2gme>.

Moataz Dowaidar. Many miRNAs Participate in Inflammatory Regulation and Bone Metabolism. Overexpression of miR21 and miR155 Releases Proinflammatory Cytokines. <https://doi.org/10.31219/osf.io/2wuvp>.

Moataz Dowaidar. MiR490's Diagnostic Capacity Was Demonstrated in Various Cancer Kinds and Diseases, Adding to Its Clinical Value. <https://doi.org/10.31219/osf.io/wysre>.

Moataz Dowaidar. miRNAs Have an Impact on Xeno-Infectious Diseases by Influencing Host And/or Infection Factors. <https://doi.org/10.31219/osf.io/7qewx>.

Moataz Dowaidar. Mutations in MED12 Lead to Mental Retardation, Including Opitz–Kaveggia Syndrome, Ohdo Syndrome, Lujan–Fryns Syndrome, and Psychosis. It's a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/cyns8>.

Moataz Dowaidar. Nanocarriers Can Be Used to Control the Activity of Genome Editing in a Spatiotemporal Way by Using Stimulusresponsive Nanocarriers. <https://doi.org/10.31219/osf.io/nua89>.

Moataz Dowaidar. Nanomaterials Were Formed into Various Shapes, with Functionalization Aimed at Various Internalization Processes. Their Nanoscale Size Allows Drugs to Reach Cells or Extracellular Environments. <https://doi.org/10.31219/osf.io/p2ajv>.

Moataz Dowaidar. Nanomedicine Is Offering Promising Strategies for Tumor Blockade Treatment. <https://doi.org/10.31219/osf.io/yzxuq>.

Moataz Dowaidar. Network Medicine Might Lead to New Treatments for Dyslipidemia. It Will Be a Challenging Method to Implement in a Clinical Context. <https://doi.org/10.31219/osf.io/nksbw>.

Moataz Dowaidar. Neuroinflammation Caused by Activated Microglia and Astrocytes Can Contribute to the Progression of Pathogenic Damage to Substantia Nigra Neurons, Playing a Role in Parkinson's Disease Progression. <https://doi.org/10.31219/osf.io/ac896>.

Moataz Dowaidar. Neurologists Rarely Perform Genetic Testing for Parkinson's Disease. Evidence Suggests That Many Patients with Major Genetic Variants Go Undiagnosed. <https://doi.org/10.31219/osf.io/ykpb2>.

Moataz Dowaidar. Neuronal Intranuclear Hyaline Inclusion Disease Is a Neurodegenerative Condition Which Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/upgqd>.

Moataz Dowaidar. New Therapies Aim at Restoring the Molecular, Morphological, and Functional Integrity of Parkinson's Specific Brain Circuits. <https://doi.org/10.31219/osf.io/dvyxc>.

Moataz Dowaidar. Not All lncMIRHGs Are 'Junk Transcripts,'. lncMIRHG Loci May Make Both Functional miRNAs and lncRNAs, Which Can Work Together or Separately. <https://doi.org/10.31219/osf.io/a567w>.

Moataz Dowaidar. Nrf2 Signaling Pathways Are Part of a Wider Network of Signaling Pathways Regulating Thymoquinone Therapeutic Actions Which Need Innovative Formulations and Delivery Methods. <https://doi.org/10.31219/osf.io/u2fa7>.

Moataz Dowaidar. Omics Should Be Integrated with Genomics to Uncover Molecular Networks and Tissue and Single-Cell Epigenetic Changes. With These Findings, Targeted Pseudoexfoliation Syndrome and Glaucoma Gene Therapy Procedures May Be Viable. <https://doi.org/10.31219/osf.io/48fj5>.

Moataz Dowaidar. Ophthalmic Gene and Cell Therapies. <https://doi.org/10.31219/osf.io/n84m9>.

Moataz Dowaidar. p21 Is a Flexible, Multi-Functional Protein. It Governs Various Tumor Cell Activities, Including Autophagy. p21 Is a Possible Radiotherapy Target. <https://doi.org/10.31219/osf.io/ydkca>.

Moataz Dowaidar. Parkinson's Disease Simulating Complexity via Improving the Identification of Significant Genetic Alterations and Environmental Contaminants Should Be a Priority. <https://doi.org/10.31219/osf.io/pmcu9>.

Moataz Dowaidar. Patient-Specific Microphysiology Systems Are Likely to Become a Crucial Aspect of Translational Research and Precision Medicine. <https://doi.org/10.31219/osf.io/bc8fr>.

Moataz Dowaidar. Patients with PMD Who Are Thoroughly Screened by Genomic Medicine Have a Considerable Chance of Benefiting Greatly from Whole-Genome Sequencing. <https://doi.org/10.31219/osf.io/dajft>.

Moataz Dowaidar. Polydopamine Nanoparticles' Activity and Long-Term Stability Should Be Fully Studied for Gene Therapy Applications. <https://doi.org/10.31219/osf.io/x4nej>.

Moataz Dowaidar. Potential Therapeutics for Primary Mitochondrial Disorders. <https://doi.org/10.31219/osf.io/6pz5k>.

Moataz Dowaidar. Potentials of Medicinal Nanostructured Diamond Particles and Coatings. <https://doi.org/10.31219/osf.io/h68xz>.

Moataz Dowaidar. Preclinical Investigations Revealed Possibilities for Salmonella Tumor Treatment. Bacteria Can Also Be Coupled to Nanomaterials Enabling Drug-Loading, Photocatalytic And/or Magnetic Properties, Using the Bacteria's Net Negative Charge. <https://doi.org/10.31219/osf.io/embqk>.

Moataz Dowaidar. Research into P2X Purinergic Receptor Function in Tumor Growth Has Made Substantial Progress with Potential Gene Therapy Targeting. <https://doi.org/10.31219/osf.io/r34fs>.

Moataz Dowaidar. RNA Therapies Hold Great Promise for Treating Cancer. High-Throughput Screening Techniques Have Facilitated the Development of RNA Treatments. <https://doi.org/10.31219/osf.io/9vxrb>.

Moataz Dowaidar. RNAi Treatment Has Been Shown to Successfully Modify Human-Related Target Gene Expression, Including Cancer. It Has the Capacity to Control Non-Standard Oncogenes, such as Oncogenic lncRNAs. <https://doi.org/10.31219/osf.io/bwqep>.

Moataz Dowaidar. RNAs Hold a Lot of Potential When It Comes to Druggable Molecular Targets. <https://doi.org/10.31219/osf.io/2dtgx>.

Moataz Dowaidar. Shadow Enhancers' Objective Seems to Be to Establish Robust Growth Patterns Independent of Genetic or Environmental Stress. <https://doi.org/10.31219/osf.io/qfnkp>.

Moataz Dowaidar. Sickle Cell Disease Hematopoietic Stem Cell Gene Therapy with Globin Gene Addition Is Promising. <https://doi.org/10.31219/osf.io/j5fkb>.

Moataz Dowaidar. Single-Gene Mutations in mtDNA-Associated Proteins Are Unlikely to Be the Main Cause of Sporadic Parkinson's Disease. Cumulative Genetic Variation in Numerous Genes May Be Important in Neurodegeneration and PD Risk. <https://doi.org/10.31219/osf.io/89qte>.

Moataz Dowaidar. Small Nuclear Ribonucleoproteins (snRNPs) Based Gene Therapy. <https://doi.org/10.31219/osf.io/c43r9>.

Moataz Dowaidar. Studying the Pathologic Mechanisms of Osteoporosis and the Bone Microenvironment May Help Researchers Better Know the Etiology of Rheumatoid Arthritis, Periodontitis, and Multiple Myeloma, as Well as Other Inflammatory and Autoimmune Disorders. <https://doi.org/10.31219/osf.io/t3z6y>.

Moataz Dowaidar. Suicide Gene Therapy May Be Effective in the Treatment of Malignant Glioma. <https://doi.org/10.31219/osf.io/vdkst>.

Moataz Dowaidar. Synuclein Is a Protein That Is Expressed in Brain Tissue. The Specific Missense Mutation (SNCA) Found in a Family with Parkinson's Disease Is the Cause. Other Diseases Include Alzheimer's Disease and REM Sleep Behavior Disorder. <https://doi.org/10.31219/osf.io/bs8rc>.

Moataz Dowaidar. Systems Biology Is a Method for Analyzing Massive Amounts of Multidimensional Data Generated by Omics Technologies. Cross-Validation of the Various Technological Platforms Is Critical. <https://doi.org/10.31219/osf.io/p8vkd>.

Moataz Dowaidar. Targeting Mitochondria and Especially Taz Gene Mutation Induces CL May Give Novel Therapeutic Alternatives for Treating Barth Syndrome. <https://doi.org/10.31219/osf.io/unfpy>.

Moataz Dowaidar. The Ability to Combine Multiple mRNA Antigens Targeting Multiple Pathogens Simultaneously, and the Robust Immune Responses Are Confirmed in Several Clinical Studies. <https://doi.org/10.31219/osf.io/6qksx>.

Moataz Dowaidar. The Cubic Polyhedral Oligomeric Silsesquioxanes Based Hybrid Materials Have a Wide Variety of Applications, Including Drug Administration, Gene Therapy, Biological Imaging, and Bone Regeneration. <https://doi.org/10.31219/osf.io/9peq8>.

Moataz Dowaidar. The Development of Tissue Replacement Therapies and Drug Discovery Was a Critical Milestone in Advancing Regenerative Medicine. <https://doi.org/10.31219/osf.io/w9bsm>.

Moataz Dowaidar. The Epidemic of COVID-19 Prompted Widespread Use of mRNA Vaccinations. <https://doi.org/10.31219/osf.io/jqws5>.

Moataz Dowaidar. The Most Useful and Commonly Available Acute Rejection Surveillance Strategies Are Routine Monitoring of Myocardial Function and Donor-Specific Anti-HLA Abs Monitoring. <https://doi.org/10.31219/osf.io/ebw68>.

Moataz Dowaidar. The Protease MBTPS2 Is an Important Regulator of Several Cellular Processes, Especially in Health and Sickness. <https://doi.org/10.31219/osf.io/qyn6h>.

Moataz Dowaidar. The Sigma 1 Receptor (S1R) Is a Potential Therapeutic Target for the Treatment of Huntington's Disease. <https://doi.org/10.31219/osf.io/mcefx>.

Moataz Dowaidar. The Use of a Network Medicine Approach Might Result in Innovative Strategies for Lowering Coronary Heart Disease and CV Risks. <https://doi.org/10.31219/osf.io/eakg8>.

Moataz Dowaidar. The Vasoconstrictor Endothelin System Involvement in Chronic Kidney Diseases Pathogenesis Is Now the Most Often Employed Treatment Method. <https://doi.org/10.31219/osf.io/cnkqy>.

Moataz Dowaidar. The VPS35-D620N Mutation Is Associated with Parkinson's Disease and Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/83sxx>.

Moataz Dowaidar. Therapeutics Including Gene Therapy for Osteoarthritis as a Concept. <https://doi.org/10.31219/osf.io/7zsqy>.

Moataz Dowaidar. Tissue Hypoxia Has Been Established as a Master Regulator for Alternative Splicing, with Substantial Clinical Consequences and Possibilities for Gene Therapy Targeting. <https://doi.org/10.31219/osf.io/5pbw4>.

Moataz Dowaidar. To Rectify Alzheimer's Disease Etiology, Excessive Mitochondrial Division Might Be Stopped or Mitophagy Might Be Promoted. <https://doi.org/10.31219/osf.io/6kdxw>.

Moataz Dowaidar. Transcriptomics Is a Rapidly Growing Field That Generates New Data That May Be Used on Its Own or in Combination with Existing Clinical Data for Development of New Therapeutics, Including Gene Therapy. <https://doi.org/10.31219/osf.io/kfr6a>.

Moataz Dowaidar. Tumor Microenvironment Has Clinical Significance in Terms of Prognosis and Therapy Prediction. <https://doi.org/10.31219/osf.io/4dz8q>.

Moataz Dowaidar. Using AAV as a Gene Delivery Vector in the Neural System Is Effective in Several Animals, such as Nonhuman Primates. <https://doi.org/10.31219/osf.io/ut4fa>.

Moataz Dowaidar. Using Pre-Existing Datasets to Combine Published Information with New Metrics Would Help Researchers Construct a Broader Picture of Chromatin in Disease. <https://doi.org/10.31219/osf.io/gsqv5>.

Moataz Dowaidar. Virus-like Particles Are Good Nanocarriers for Liquid Biopsy Probes, Imaging Contrast Agents, and Anticancer Medications. <https://doi.org/10.31219/osf.io/xbtka>.

- Moataz Dowaidar. ZEB1 Controls the Expression of ICAM1, Promoting Monocyte-Macrophage Adhesion and Hence the Formation of Atherosclerotic Lesions. <https://doi.org/10.31219/osf.io/kzjqg>.
- Moataz Dowaidar. Gene Therapy Development and Legislation. <https://doi.org/10.31219/osf.io/mwb2n>.
- Moataz Dowaidar. Next-Generation Sequencing Is Now Utilized to Identify Genetic Abnormalities and Develop Gene Therapy. <https://doi.org/10.31219/osf.io/em7xp>.
- Moataz Dowaidar. Nucleic Acid Designs, Artificial Intelligence for Screening Nanomaterials, and Enhanced Characterization Methods Are Needed to Make Nanomedicine More Successful. <https://doi.org/10.31219/osf.io/2w5aq>.
- Moataz Dowaidar. Potential Strategies for Cancer Gene Therapy. <https://doi.org/10.31219/osf.io/atcqz>.
- Moataz Dowaidar. Quantitative Groups Will Be Critical to the Success of Future Gene Therapy Programs. <https://doi.org/10.31219/osf.io/v97ht>.
- Moataz Dowaidar. The Treatment of Major Human Illnesses with Recombinant Adeno-Associated Virus (rAAV) Has Shown Tremendous Promises. <https://doi.org/10.31219/osf.io/uwa4e>.
- Moataz Dowaidar. Carbon Nanotubes Have Enormous Potential in Gene Therapy. <https://doi.org/10.31219/osf.io/9bcxk>.
- Moataz Dowaidar. Charge-Alteration-Based Approaches Can Address the Evolving Needs of Nucleic Acid-Based Gene Therapy, Charge Reversal Techniques Are Also Promising. <https://doi.org/10.31219/osf.io/zwq5h>.
- Moataz Dowaidar. Chromosome X, the Most Explored Genome-Editing Chromosome, Presents Possibilities for Hemophilia A Treatments. <https://doi.org/10.31219/osf.io/6vsdz>.
- Moataz Dowaidar. Clinical Investigations Show That siRNA May Be Used to Treat a Variety of Disorders, Including Cancer. <https://doi.org/10.31219/osf.io/fcsgq>.
- Moataz Dowaidar. Cyclodextrins as Potential Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/zhtsc>.
- Moataz Dowaidar. Development of Specialized Carriers Capable of Delivering Effective RNAi and siRNA Gene Therapy. <https://doi.org/10.31219/osf.io/3ykwmm>.
- Moataz Dowaidar. Gene Therapy Can Target Mutations such as BRAF, Which Have Been Shown to Make Tumors More Susceptible to Autophagy Suppression. <https://doi.org/10.31219/osf.io/3gwra>.
- Moataz Dowaidar. Gene Therapy Vectors Should Enable CRISPR Systems to Accumulate at Disease Sites and Successfully Penetrate Nuclei. <https://doi.org/10.31219/osf.io/xzmmnc>.
- Moataz Dowaidar. Nanoformulations Can Be Utilized to Deliver Effective siRNA to Tumor Cells to Decrease Gene Expression. <https://doi.org/10.31219/osf.io/zvukc>.
- Moataz Dowaidar. Neuronal Ceroid Lipofuscinosis Therapeutics. <https://doi.org/10.31219/osf.io/75vcp>.
- Moataz Dowaidar. Nonviral Gene Delivery Vectors for Transfection of the CAR Gene for CAR-T Cell Therapy. <https://doi.org/10.31219/osf.io/ckxh5>.
- Moataz Dowaidar. Potential HIV Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/e5hm2>.
- Moataz Dowaidar. Research on Cell Sources for Brain Cell Replacement Methods Has Gained Major Importance. Cell and Gene Therapy Are Potentially Intriguing New Domains of Regenerative Medicine. <https://doi.org/10.31219/osf.io/g835b>.
- Moataz Dowaidar. RNAi-Based Gene Therapy Provides a Wide Variety of Applications. Safe, Biodegradable Nano Delivery Vectors Are Still Needed. <https://doi.org/10.31219/osf.io/s2zhn>.
- Moataz Dowaidar. Strategies for Treating Multiple Sclerosis with Gene Therapy. <https://doi.org/10.31219/osf.io/syncn6>.
- Moataz Dowaidar. The Combination of Unique Biomolecules and Nanoparticles Has Shown Successful Gene Therapy Treatment Approaches for Non-Small Cell Lung Cancer Treatment. <https://doi.org/10.31219/osf.io/yeq5z>.
- Moataz Dowaidar. Understanding Why the Same Gene Delivery Vector Behaves Differently in Different Cell Types Is Essential for Developing More Adaptable Transfection Systems. <https://doi.org/10.31219/osf.io/6q8af>.
- Moataz Dowaidar. AAV9 Is Considered the Most Efficient AAV Serotype Targeting Blood-Brain Barriers. To Enhance Effective Gene Therapy for CNS Illnesses, Testing Novel Vectors with More Efficient Crossing Capabilities Is Vital. <https://doi.org/10.31219/osf.io/7bf5s>.
- Moataz Dowaidar. Artificial miRNAs Are Potential Gene Therapy Tools, Especially for Incurable Monogenic Disorders. <https://doi.org/10.31219/osf.io/d5rnm>.

- Moataz Dowaidar. Breakthroughs in mRNA Modification and Nanoparticle-Based Delivery Vehicles Facilitate Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/ky7dt>.
- Moataz Dowaidar. CRISPR/Cas9-Mediated Genome Editing Has Demonstrated Significant Promise for Genetic Correction in Autologous Hematopoietic Stem/progenitor Cells (HSPCs) and Induced Pluripotent Stem Cells (iPSCs). <https://doi.org/10.31219/osf.io/xk54r>.
- Moataz Dowaidar. Gene Therapy Vectors for Targeting the Heart. <https://doi.org/10.31219/osf.io/gcbhf>.
- Moataz Dowaidar. Liposomes Can Minimize Cardiotoxicity, Address Drug Resistance, and Improve Overall Drug Release Profiles in Breast Cancer. <https://doi.org/10.31219/osf.io/tn56d>.
- Moataz Dowaidar. Liposomes with Cerasome-Forming Lipids as Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/zjn6v>.
- Moataz Dowaidar. Nanomaterials Combine Multiple Therapeutic Approaches for Cancer Cell Multidrug Resistance, Ferroptotic Cell Death Is Promising in Various Cancers. <https://doi.org/10.31219/osf.io/7bg9t>.
- Moataz Dowaidar. Nanomedicines for Enhanced Permeability and Retention (EPR)-Stratified Patients Have the Potential to Improve Treatment Outcomes. <https://doi.org/10.31219/osf.io/xrcb2>.
- Moataz Dowaidar. RNA-Based Gene Therapy for Manipulating the Neuroinflammatory Cascade Closely Linked to Neurodegeneration Can Help Reduce Disease Development. <https://doi.org/10.31219/osf.io/2hswv>.
- Moataz Dowaidar. Targeted Chemical Nucleases Have a Wide Range of Untapped Applications in Biological Fields, Including Gene Therapy. <https://doi.org/10.31219/osf.io/6bexs>.
- Moataz Dowaidar. Bacterial Nanoparticles Can Deliver Proteins, Medications, Enzymes, and Genes to Diagnose and Cure Numerous Illnesses. <https://doi.org/10.31219/osf.io/7gyna>.
- Moataz Dowaidar. Exosomal miRNA Diagnostic and Gene Therapy Tools. <https://doi.org/10.31219/osf.io/aknrc>.
- Moataz Dowaidar. Gene Modification Research Has Potential, from Diagnostic to Therapeutic Levels. The Most Promising Metabolic Pathways Include the TGF-1 Signaling System, Inflammation and Protein Transport. <https://doi.org/10.31219/osf.io/5ert4>.
- Moataz Dowaidar. Gene Therapy Using MnO₂ Nanoparticles. <https://doi.org/10.31219/osf.io/xmwjs>.
- Moataz Dowaidar. Gene-Regulatory Elements May Change the Amount, Timing, or Location of Gene Expression, Cis-Regulation Therapy Platforms Might Become a Gene Therapy to Treat Many Genetic Diseases. <https://doi.org/10.31219/osf.io/xk5a2>.
- Moataz Dowaidar. Hemophilia Therapeutics. <https://doi.org/10.31219/osf.io/gu74x>.
- Moataz Dowaidar. Mesenchymal Stem Cells Strategies in Cancer Immunotherapy. <https://doi.org/10.31219/osf.io/dkv6w>.
- Moataz Dowaidar. Nanomaterials Can Inhibit Planktonic and Biofilm Bacteria and Can Be Used as Topical Therapy for Mouth and Wound-Related Infections. <https://doi.org/10.31219/osf.io/aqd2e>.
- Moataz Dowaidar. New Technologies to Improve CAR T Cell Generation and Biomanufacturing Will Lead to Safer, More Therapeutically Effective Cells. <https://doi.org/10.31219/osf.io/un8gp>.
- Moataz Dowaidar. Ocular Gene Therapy Strategies. <https://doi.org/10.31219/osf.io/7en3k>.
- Moataz Dowaidar. Peripheral Nerve Injury Therapeutics, Including Electrical Stimulation, Stem Cell Treatments, and Synthetic Neural Scaffolds, Have Shown Promising Preclinical and Even Clinical Results with Potential Regenerative Treatment. <https://doi.org/10.31219/osf.io/m8cs9>.
- Moataz Dowaidar. Photothermal and Photodynamic Photoactivation of Nanomaterials-Based Prodrugs Are Two Key Methods for NIR Light-Mediated Photoactivation. <https://doi.org/10.31219/osf.io/2bh3r>.
- Moataz Dowaidar. Quantum Dots Have the Potential to Be Used in Gene Therapy. <https://doi.org/10.31219/osf.io/bdeg6>.
- Moataz Dowaidar. Sickle Cell Disease Has Emerged as a Public Health Concern. Some Drugs May Conflict with Curative Therapies, yet They May Be Useful as a Bridge to HSCT and Gene Therapy. <https://doi.org/10.31219/osf.io/6kufh>.
- Moataz Dowaidar. Stimulator of Interferon Genes (STING)-Activating Nanoparticles Can Be Employed as a Tool for Controlled Immune Activation. <https://doi.org/10.31219/osf.io/2ez7a>.
- Moataz Dowaidar. CRISPR/Cas9 Has Introduced New Gene Therapy Possibilities for Muscular Dystrophies. <https://doi.org/10.31219/osf.io/ug8v4>.

- Moataz Dowaidar. Degradable Branched Polycationic Systems Are Promising Gene Therapy Vectors. <https://doi.org/10.31219/osf.io/utpf>.
- Moataz Dowaidar. Developing Nanotechnology Platforms for Peptide-Based Combinatory Cancer Gene Therapy Will Likely Have a Significant Influence on the Development of Personalized Cancer Medicines. <https://doi.org/10.31219/osf.io/zbrkj>.
- Moataz Dowaidar. Exosomes May Prevent Cardiac Attacks, Heart Failure, and Cardiomyopathy. <https://doi.org/10.31219/osf.io/agm3k>.
- Moataz Dowaidar. 2021gr. Exosomes Potential Therapeutics. <https://doi.org/10.31219/osf.io/mhwt3>.
- Moataz Dowaidar. Gene Therapy Using miRNA Treatment Suppresses the Expression of Bone-Forming Defective Genes and Raises the Expression of Genes That Become Dormant during Bone Building. <https://doi.org/10.31219/osf.io/tcka3>.
- Moataz Dowaidar. Genome-Editing Is Promising for Producing Therapeutically Relevant Animal Models for Possible Therapies for Rare Human Diseases. <https://doi.org/10.31219/osf.io/dehr9>.
- Moataz Dowaidar. Human Corneal Endothelial Cells Grafts to Replace Cadaveric Donor Corneas. <https://doi.org/10.31219/osf.io/p9x7e>.
- Moataz Dowaidar. Hybrid Nanotechnology and Peptide Nucleic Acid Could Improve the Effectiveness of Gene Therapy by Increasing Its Cell Permeability. <https://doi.org/10.31219/osf.io/d8wzt>.
- Moataz Dowaidar. In Prenatal Stem Cell Transplantation and in Utero Gene Therapy, a Wide Spectrum of Genetic Diseases Can Be Diagnosed and Treated before Birth. <https://doi.org/10.31219/osf.io/sa3vz>.
- Moataz Dowaidar. Magnetic Iron Oxide Nanoparticles Have Potential on Gene Therapy Effectiveness and Biocompatibility. <https://doi.org/10.31219/osf.io/f3hm4>.
- Moataz Dowaidar. Neurotrophin Gene Therapy May Be Able to Treat Individuals with Noise-Induced Hearing Loss or Neural Presbycusis. <https://doi.org/10.31219/osf.io/spkxh>.
- Moataz Dowaidar. Plant Viral Nanoparticles Can Be Used in Biological Systems for Loading and Transporting Cargo. <https://doi.org/10.31219/osf.io/txdka>.
- Moataz Dowaidar. Polydopamine May Be Easily Functionalized with a Range of Nanomaterials for Synergistic Cancer Therapy, in Addition to Its Exceptional Photothermal Effects. <https://doi.org/10.31219/osf.io/cq942>.
- Moataz Dowaidar. Tumor-Targeted Drug Delivery Systems for Anticancer Therapies Can Selectively Provide an Appropriate Cytotoxic Payload to Cancer Cells, Reducing the Side Effects of Chemo. <https://doi.org/10.31219/osf.io/683nj>.
- Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Krista Freimann, Kaido Kurrikoff, Xiaodong Zou, and Ülo Langel. 2017. Magnetic Nanoparticle Assisted Self-Assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery. *Scientific Reports* 7 (1): 9159. <https://doi.org/10.1038/s41598-017-09803-z>.
- Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. Supplemental Material for Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles–cell-Penetrating Peptide. *SAGE Journals*. <https://doi.org/10.25384/SAGE.7105436.V1>.
- Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Xiaodong Zou, and Ülo Langel. 2017. Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery General Subjects. *Biochimica et Biophysica Acta, General Subjects*. <https://pubag.nal.usda.gov/catalog/5734174>.
- Moataz Dowaidar. 2017. Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery. *Biochimica et Biophysica Acta, General Subjects* 1861 (9): 2334–41. <https://doi.org/10.1016/j.bbagen.2017.07.002>.
- Dowaidar, Moataz, and Moataz Dowaidar. 2018. Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis.
- Moataz Dowaidar. Addiction Biology Research on miRNAs, and Their Role in the Pathophysiology of Addiction Is Enabling Gene Therapy Opportunities. <https://doi.org/10.31219/osf.io/z5wyt>.
- Moataz Dowaidar. Aptamers Targeting Vascular Endothelial Growth Factor Molecular Regulation as Potential Therapists. <https://doi.org/10.31219/osf.io/a8qpr>.
- Moataz Dowaidar. Arrhythmogenic Cardiomyopathy Is a Set of Hereditary Cardiac Muscle Disorders Where Various Etiologies Converge. Most ACM Patients Do Not Have a Genetic Diagnosis. <https://doi.org/10.31219/osf.io/pzstv3>.

Moataz Dowaidar. Autophagy, Immunological Response, and Inflammation All Rely on the TRIM Family Proteins. TRIM-Based Therapeutics for Inflammatory Illnesses Including Diabetes and Diabetic Comorbidities Are Promising. <https://doi.org/10.31219/osf.io/y4g6e>.

Moataz Dowaidar. Biogenic Particles Can Be Multiantigenic, Immunostimulative and Activate Innate Immunity While Suppressing Tumor Development. <https://doi.org/10.31219/osf.io/q2kby>.

Moataz Dowaidar. Biological Medications for Interventional Pain Have a Lot of Clinical Data behind Them. It Is Fair to Assume They Will Replace Steroid-Based Interventional Techniques, Providing Patients with Longer Relief. <https://doi.org/10.31219/osf.io/4y5fm>.

Moataz Dowaidar. Carbon Nanofibers Assist in the Manufacture of Prosthetic Joints, Promote Tissue, Organ, Nerve Regeneration and Development, and Improve Anticancer Therapy Impact and Chemosensitization for a Range of Tumor Types. <https://doi.org/10.31219/osf.io/z3ucn>.

Moataz Dowaidar. Emerging Therapy Options May Help Patients with RAG Deficiency, Especially Those with Severe Immune Dysregulation. <https://doi.org/10.31219/osf.io/v5tjg>.

Moataz Dowaidar. Exosomes as Promising Gene Therapy Tools Still Need to Be Researched and Manufactured More Efficiently. <https://doi.org/10.31219/osf.io/nw4z7>.

Moataz Dowaidar. Focus on Exosomes Could Help Make the Use of Circulating miRNA as Biomarkers More Practical. A Detailed Understanding of miRNA Behavior Should Be a Subject of Gene Therapy. <https://doi.org/10.31219/osf.io/uan6x>.

Moataz Dowaidar. Gene-Free Viral-like Particles (VLPs) Offer a Safer Alternative to Inactivating or Weakening Viral Strains for Traditional Vaccines. VLP-Based Vaccinations without Adjuvants Have Been Found to Promote Humoral and Cellular Immunity. <https://doi.org/10.31219/osf.io/9dvut>.

Moataz Dowaidar. Given the Importance of mTOR Signaling in a Number of Illnesses, It Looks Suitable to Use miR 99 Family Members as a Therapeutic Intervention to Deal with These Illnesses by Using Gene Therapy Tools. <https://doi.org/10.31219/osf.io/8cwgh>.

Moataz Dowaidar. HMGB1 Has Sparked a Lot of Attention as a Model DAMP Molecule Involved in Inflammation, Inflammatory Diseases, and Cancer. <https://doi.org/10.31219/osf.io/5qx36>.

Moataz Dowaidar. Nucleic Acid Nanocarriers Can Be Programmable, Spatially Adjustable and Biocompatible, Minimizing Systemic Toxicity and Improving Pharmacodynamics. <https://doi.org/10.31219/osf.io/wr237>.

Moataz Dowaidar. Osteoporosis Is a Prominent Source of Morbidity and Mortality in the Elderly, Particularly in Postmenopausal Women. Long Noncoding RNAs (lncRNAs) Have Been Found to Be Important Regulators and Possible Gene Therapy Targets. <https://doi.org/10.31219/osf.io/ghfpt>.

Moataz Dowaidar. Polycomb Genes Role in Cancer Pathophysiology Is Offering Targets for Therapeutics Including Gene Therapy. <https://doi.org/10.31219/osf.io/sfvej>.

Moataz Dowaidar. RNA Sequencing and Microarray Analysis Are Helpful Techniques to Detect Obesity-Related lncRNAs. lncRNA Can Alter Cholesterol Metabolism and Can Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/3fb6w>.

Moataz Dowaidar. Sepsis-Associated Acute Kidney Damage Is a Disease That Affects the Patient's Quality of Life. It Should Be a Target for Gene Therapy. <https://doi.org/10.31219/osf.io/49k7q>.

Moataz Dowaidar. The Gene Expression Profiling Gives an in-Depth Insight of Breast Cancer Heterogeneity, Better than a Single Protein or Gene Expression. It Is Time to Include It in the Daily Routine. <https://doi.org/10.31219/osf.io/xhyd7>.

Moataz Dowaidar. The Nanomedicine System Has Successfully Inhibited Tumor Neovascularization Using Gene Silencing, Chemotherapy, Photothermal Therapy, and Other Therapies. <https://doi.org/10.31219/osf.io/rk2bf>.

Moataz Dowaidar. The Therapeutic Application of a Nucleic Acid Sequence to Patients' Diseased Organs Is Currently Available. <https://doi.org/10.31219/osf.io/pqsbfb>.

Moataz Dowaidar. Triple-Negative Breast Cancer, Which Lacks the Expression of Hormone Receptors and HER2, Has a Worse Prognosis. Massive Parallel Sequencing Is Capable of Reliably Breaking down the Intra-Tumor and Inter-Tumor Heterogeneity. <https://doi.org/10.31219/osf.io/pvk7u>.

Dowaidar, Moataz, H. A. Ismail, A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region. Egyptian Journal of Biochemistry and Molecular Biology 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.

- Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles-Cell-Penetrating Peptide. *Journal of Biomaterials Applications* 33 (3): 392–401. <https://doi.org/10.1177/0885328218796623>.
- Dowaidar, Moataz, and Ahmad Settin. 2010. Risk of Myocardial Infarction Related to Factor V Leiden Mutation: A Meta-Analysis. *Genetic Testing and Molecular Biomarkers* 14 (4): 493–98. <https://doi.org/10.1089/gtmb.2010.0017>.
- Gestin, Maxime, Moataz Dowaidar, and Ülo Langel. 2017. Uptake Mechanism of Cell-Penetrating Peptides. *Advances in Experimental Medicine and Biology* 1030: 255–64. https://doi.org/10.1007/978-3-319-66095-0_11.
- Ismail, H. A., A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region. *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.
- Settin, Ahmad A., Abdullah Alghasham, Moataz Dowaidar, and Hisham Ismail. 2009. Methylene Tetrahydrofolate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms Related to Overweight/obesity among Saudi Subjects from Qassim Region. *Disease Markers* 27 (2): 97–102. <https://doi.org/10.3233/DMA-2009-0660>.
- Settin, Ahmad A., Abdullah Alghasham, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012. Frequency of Thrombophilic Genetic Polymorphisms among Saudi Subjects Compared with Other Populations. *Hematology* 17 (3): 176–82. <https://doi.org/10.1179/102453312X13376952196575>.
- Settin, Ahmad, Ibrahim S. Abu-Saif, Rizk El-Baz, Moataz Dowaidar, Rabab Abu-Al Kasim, and Shaimaa Shabana. 2007a. Diagnosis of Sex Chromosome Disorders and Prenatal Diagnosis of Down Syndrome Using Interphase Fluorescent In-Situ Hybridization Technique. *International Journal of Health Sciences* 1 (2): 203–9. <https://www.ncbi.nlm.nih.gov/pubmed/21475429>.
- Settin, Ahmad, Abdullah Alghasham, Moataz Dowaidar, and Hisham Ismail. 2011. Methylene Tetrahydrofolate Reductase (MTHFR) and Angiotensinogen Converting Enzyme (ACE) Gene Polymorphisms Related to Overweight and Obesity among Saudi Patients in Al Qassim. *International Journal of Health Sciences* 5 (2 Suppl 1): 24–25. <https://www.ncbi.nlm.nih.gov/pubmed/23284565>.
- Settin, Ahmad, Hala Almarsafawy, Ahmad Alhussieny, and Moataz Dowaidar. 2008a. Dysmorphic Features, Consanguinity and Cytogenetic Pattern of Congenital Heart Diseases: A Pilot Study from Mansoura Locality, Egypt. *International Journal of Health Sciences* 2 (2): 101–11. <https://www.ncbi.nlm.nih.gov/pubmed/21475491>.
- Settin, Ahmad, Moataz Dowaidar, Rizk El-Baz, Ayman Abd-Al-Samad, Ibrahim El-Sayed, and Mahmoud Nasr. 2008. Frequency of Factor V Leiden Mutation in Egyptian Cases with Myocardial Infarction. *Hematology* 13 (3): 170–74. <https://doi.org/10.1179/102453308X316158>.
- Venit, Tomas, Moataz Dowaidar, Maxime Gestin, Syed Raza Mahmood, Ülo Langel, and Piergiorgio Percipalle. 2020. Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to Be Part of a Common Response to Cell-Penetrating Peptides. *Biomolecules* 10 (11): 1567. <https://doi.org/10.3390/biom10111567>.
- Moreau, T., Evans, A. L., Vasquez, L., Tijssen, M. R., Yan, Y., Trotter, M. W., Howard, D., Colzani, M., Arumugam, M., Wu, W. H., Dalby, A., Lampela, R., Bouet, G., Hobbs, C. M., Pask, D. C., Payne, H., Ponomaryov, T., Brill, A., Soranzo, N., ... Ghevaert, C. (2016). Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. *Nat. Commun.* 7, 11208. <https://doi.org/10.1038/ncomms11208>
- Nakagawa, Y., Nakamura, S., Nakajima, M., Endo, H., Dohda, T., Takayama, N., Nakauchi, H., Arai, F., Fukuda, T., & Eto, K. (2013). Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. *Exp. Hematol.* 41, 742–748. <https://doi.org/10.1016/j.exphem.2013.04.007>
- Nakamura, S., Takayama, N., Hirata, S., Seo, H., Endo, H., Ochi, K., Fujita, K.-I., Koike, T., Harimoto, K.-I., Dohda, T., Watanabe, A., Okita, K., Takahashi, N., Sawaguchi, A., Yamanaka, S., Nakauchi, H., Nishimura, S., & Eto, K. (2014). Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. *Cell Stem Cell*, 14, 535–548. <https://doi.org/10.1016/j.stem.2014.01.011>
- Navarro, S., Debili, N., Le Couedic, J. P., Klein, B., Breton-Gorius, J., Doly, J., & Vainchenker, W. (1991). Interleukin-6 and its receptor are expressed by human megakaryocytes: In vitro effects on proliferation and endoreplication. *Blood*, 77, 461–471. <https://doi.org/10.1182/blood.V77.3.461.461>

Nishi, E. (2013). Nardilysin. In Handbook of proteolytic enzymes, N. Rawlings and G. Salvesen, eds. (London: Academic Press) (vol. 1, pp. 1421–1426).
Crossref Google Scholar

Nishimura, S., Nagasaki, M., Kunishima, S., Sawaguchi, A., Sakata, A., Sakaguchi, H., Ohmori, T., Manabe, I., Italiano, J. E., Ryu, T., Takayama, N., Komuro, I., Kadowaki, T., Eto, K., & Nagai, R. (2015). IL-1 α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. *J. Cell Biol.* 209, 453–466. <https://doi.org/10.1083/jcb.201410052>

Nishimura, T., Kaneko, S., Kawana-Tachikawa, A. I., Tajima, Y., Goto, H., Zhu, D., Nakayama-Hosoya, K., Iriguchi, S., Uemura, Y., Shimizu, T., Takayama, N., Yamada, D., Nishimura, K., Ohtaka, M., Watanabe, N., Takahashi, S., Iwamoto, A., Koseki, H., Nakanishi, M., ... Nakauchi, H. (2013). Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. *Cell Stem Cell*, 12, 114–126. <https://doi.org/10.1016/j.stem.2012.11.002>

Noetzli, L. J., French, S. L., & Machlus, K. R. (2019). New insights into the differentiation of megakaryocytes from hematopoietic progenitors. *Arterioscl. Thromb. Vasc. Biol.* 39, 1288–1300. <https://doi.org/10.1161/ATVBAHA.119.312129>

Ono, Y., Wang, Y., Suzuki, H., Okamoto, S., Ikeda, Y., Murata, M., Poncz, M., & Matsubara, Y. (2012). Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf. *Blood*, 120, 3812–3821. <https://doi.org/10.1182/blood-2012-02-413617>

Osawa, M., Hanada, K. I., Hamada, H., & Nakauchi, H. (1996). Long-term lymphohematopoietic reconstitution by a single CD34⁺ low/negative hematopoietic stem cell. *Science*, 273, 242–245. <https://doi.org/10.1126/science.273.5272.242>

Palis, J., Robertson, S., Kennedy, M., Wall, C., & Keller, G. (1999). Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. *Development*, 126, 5073–5084.

Pietras, E. M., Reynaud, D., Kang, Y. A., Carlin, D., Calero-Nieto, F. J., Leavitt, A. D., Stuart, J. A., Göttgens, B., & Passegué, E. (2015). Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. *Cell Stem Cell*, 17, 35–46. <https://doi.org/10.1016/j.stem.2015.05.003>

Rodriguez-Fraticelli, A. E., Wolock, S. L., Weinreb, C. S., Panero, R., Patel, S. H., Jankovic, M., Sun, J., Calogero, R. A., Klein, A. M., & Camargo, F. D. (2018). Clonal analysis of lineage fate in native haematopoiesis. *Nature*, 553, 212–216. <https://doi.org/10.1038/nature25168>

Sanjuan-Pla, A., Macaulay, I. C., Jensen, C. T., Woll, P. S., Luis, T. C., Mead, A., Moore, S., Carella, C., Matsuoka, S., Jones, T. B., Chowdhury, O., Stenson, L., Lutteropp, M., Green, J. C. A., Facchini, R., Boukarabila, H., Grover, A., Gambardella, A., Thongjuea, S., ... Jacobsen, S. E. W. (2013). Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. *Nature*, 502, 232–236. <https://doi.org/10.1038/nature12495>

Semeniak, D., Kulawig, R., Stegner, D., Meyer, I., Schwiebert, S., Bösing, H., Eckes, B., Nieswandt, B., & Schulze, H. (2016). Proplatelet formation is selectively inhibited by collagen type I through Syk-independent GPVI signaling. *J. Cell Sci.* 129, 3473–3484. <https://doi.org/10.1242/jcs.187971>

Seemple, J. W., Italiano, J. E., & Freedman, J. (2011). Platelets and the immune continuum. *Nat. Rev. Immunol.* 11, 264–274. <https://doi.org/10.1038/nri2956>

Settin, Ahmad A., Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2009. “Methylene Tetrahydrofolate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms Related to Overweight/obesity among Saudi Subjects from Qassim Region.” *Disease Markers* 27 (2): 97–102. <https://doi.org/10.3233/DMA-2009-0660>.

Settin, Ahmad A., Abdullah Alghasham, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012. “Frequency of Thrombophilic Genetic Polymorphisms among Saudi Subjects Compared with Other Populations.” *Hematology* 17 (3): 176–82. <https://doi.org/10.1179/102453312X13376952196575>.

Settin, Ahmad, Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2011. "Methylene Tetrahydrofolate Reductase (MTHFR) and Angiotensinogen Converting Enzyme (ACE) Gene Polymorphisms Related to Overweight and Obesity among Saudi Patients in Al Qassim." *International Journal of Health Sciences* 5 (2 Suppl 1): 24–25. <https://www.ncbi.nlm.nih.gov/pubmed/23284565>.

Settin, Ahmad, Hala Almarsafawy, Ahmad Alhussieny, and Moataz Dowaidar. 2008a. "Dysmorphic Features, Consanguinity and Cytogenetic Pattern of Congenital Heart Diseases: A Pilot Study from Mansoura Locality, Egypt." *International Journal of Health Sciences* 2 (2): 101–11. <https://www.ncbi.nlm.nih.gov/pubmed/21475491>.

Settin, Ahmad, Ibrahim S. Abu-Saif, Rizk El-Baz, Moataz Dowaidar, Rabab Abu-Al Kasim, and Shaimaa Shabana. 2007a. "Diagnosis of Sex Chromosome Disorders and Prenatal Diagnosis of Down Syndrome Using Interphase Fluorescent In-Situ Hyperidization Technique." *International Journal of Health Sciences* 1 (2): 203–9. <https://www.ncbi.nlm.nih.gov/pubmed/21475429>.

Settin, Ahmad, Moataz Dowaidar, Rizk El-Baz, Ayman Abd-Al-Samad, Ibrahim El-Sayed, and Mahmoud Nasr. 2008. "Frequency of Factor V Leiden Mutation in Egyptian Cases with Myocardial Infarction." *Hematology* 13 (3): 170–74. <https://doi.org/10.1179/102453308X316158>.

Shimizu, R., Kobayashi, E., Engel, J. D., & Yamamoto, M. (2009). Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. *Genes to Cells*, 14, 1119– 1131. <https://doi.org/10.1111/j.1365-2443.2009.01338.x>

Shimizu, R., Ohneda, K., Engel, J. D., Trainor, C. D., & Yamamoto, M. (2004). Transgenic rescue of GATA-1-deficient mice with GATA-1 lacking a FOG-1 association site phenocopies patients with X-linked thrombocytopenia. *Blood*, 103, 2650–2657. <https://doi.org/10.1182/blood-2003-07-2514>

Shivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995). Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. *Cell*, 81, 695– 704. [https://doi.org/10.1016/0092-8674\(95\)90531-6](https://doi.org/10.1016/0092-8674(95)90531-6)

Silver, L., & Palis, J. (1997). Initiation of murine embryonic erythropoiesis: A spatial analysis. *Blood*, 89, 1154– 1164. <https://doi.org/10.1182/blood.V89.4.1154>

Stachura, D. L., Chou, S. T., & Weiss, M. J. (2006). Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. *Blood*, 107, 87– 97. <https://doi.org/10.1182/blood-2005-07-2740>

Stanworth, S. J., Navarrete, C., Estcourt, L., & Marsh, J. (2015). Platelet refractoriness – Practical approaches and ongoing dilemmas in patient management. *Bri. J. Haematol.* 171, 297– 305. <https://doi.org/10.1111/bjh.13597> Wiley Online Library PubMed Web of Science®Google Scholar

Strassel, C., Brouard, N., Mallo, L., Receveur, N., Mangin, P., Eckly, A., Bieche, I., Tarte, K., Gachet, C., & Lanza, F. (2016). Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. *Blood*, 127, 2231– 2240. <https://doi.org/10.1182/blood-2015-09-670208>

Strüßmann, T., Tillmann, S., Wirtz, T., Bucala, R., von Hundelshausen, P., & Bernhagen, J. (2013). Platelets are a previously unrecognised source of MIF. *Thromb. Haemost.* 110, 1004– 1013. <https://doi.org/10.1160/TH13-01-0049>

Suzuki, D., Flahou, C., Yoshikawa, N., Stirblyte, I., Hayashi, Y., Sawaguchi, A., Akasaka, M., Nakamura, S., Higashi, N., Xu, H., Matsumoto, T., Fujio, K., Manz, M. G., Hotta, A., Takizawa, H., Eto, K., & Sugimoto, N. (2020). iPSC-derived platelets depleted of HLA Class I are inert to anti-HLA Class I and Natural Killer Cell Immunity. *Stem Cell Rep.* 14, 49– 59. <https://doi.org/10.1016/j.stemcr.2019.11.011>

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*, 131, 861– 872. <https://doi.org/10.1016/j.cell.2007.11.019>

Takayama, N., Nishikii, H., Usui, J., Tsukui, H., Sawaguchi, A., Hiroyama, T., Eto, K., & Nakauchi, H. (2008). Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. *Blood*, 111, 5298– 5306. <https://doi.org/10.1182/blood-2007-10-117622>

Takayama, N., Nishimura, S., Nakamura, S., Shimizu, T., Ohnishi, R., Endo, H., Yamaguchi, T., Otsu, M., Nishimura, K., Nakanishi, M., Sawaguchi, A., Nagai, R., Takahashi, K., Yamanaka, S., Nakauchi, H., & Eto, K. (2010). Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. *J. Exp. Med.* 207, 2817– 2830. <https://doi.org/10.1084/jem.20100844>

Teramura, M., Katahira, J., Hoshino, S., Motoji, T., Oshimi, K., & Mizoguchi, H. (1988). Clonal growth of human megakaryocyte progenitors in serum-free cultures: Effect of recombinant human interleukin 3. *Exp. Hematol.* 16, 843– 848.

Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013). Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. *Nat. Biotechnol.* 31, 928– 933. <https://doi.org/10.1038/nbt.2678>

Thompson, A., Zhang, Y., Kamen, D., Jackson, C. W., Cardiff, R. D., & Ravid, K. (1996). Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization. *J. Biol. Chem.* 271, 22976– 22982.

Thomson, J. A. (1998). Embryonic stem cell lines derived from human blastocysts. *Science*, 282, 1145– 1147. <https://doi.org/10.1126/science.282.5391.1145>

Thon, J. N., Mazutis, L., Wu, S., Sylman, J. L., Ehrlicher, A., Machlus, K. R., Feng, Q., Lu, S., Lanza, R., Neeves, K. B., Weitz, D. A., & Italiano, J. E. (2014). Platelet bioreactor-on-a-chip. *Blood*, 124, 1857– 1867. <https://doi.org/10.1182/blood-2014-05-574913>

Thon, J. N., Montalvo, A., Patel-Hett, S., Devine, M. T., Richardson, J. L., Ehrlicher, A., Larson, M. K., Hoffmeister, K., Hartwig, J. H., & Italiano, J. E. (2010). Cytoskeletal mechanics of proplatelet maturation and platelet release. *J. Cell Biol.* 191, 861– 874. <https://doi.org/10.1083/jcb.201006102>

Tober, J., Koniski, A., McGrath, K. E., Vemishetti, R., Emerson, R., De Mesy-Bentley, K. K. L., Waugh, R., & Palis, J. (2007). The megakaryocyte lineage originates from hemangioblast precursors and is an integral component both of primitive and of definitive hematopoiesis. *Blood*, 109, 1433– 1441. <https://doi.org/10.1182/blood-2006-06-031898>

Tozawa, K., Ono-Uruga, Y., Yazawa, M., Mori, T., Murata, M., Okamoto, S., Ikeda, Y., & Matsubara, Y. (2019). Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line. *Blood*, 133, 633– 643. <https://doi.org/10.1182/blood-2018-04-842641>

Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013). Toward the development of a global induced pluripotent stem cell library. *Cell Stem Cell*, 13, 382– 384. <https://doi.org/10.1016/j.stem.2013.08.003>

Umekage, M., Sato, Y., & Takasu, N. (2019). Overview: An iPS cell stock at CiRA. *Inflamm. Regen.* 39, 17.

Venit, Tomas, Moataz Dowaidar, Maxime Gustin, Syed Raza Mahmood, Ülo Langel, and Piergiorgio Percipalle. 2020. Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to Be Part of a Common Response to Cell-Penetrating Peptides.” *Biomolecules* 10 (11): 1567. <https://doi.org/10.3390/biom10111567>.

Vizcardo, R., Masuda, K., Yamada, D., Ikawa, T., Shimizu, K., Fujii, S. I., Koseki, H., & Kawamoto, H. (2013). Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. *Cell Stem Cell*, 12, 31– 36. <https://doi.org/10.1016/j.stem.2012.12.006>

Wang, X., Crispino, J. D., Letting, D. L., Nakazawa, M., Poncz, M., & Blobel, G. A. (2002). Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: Role of Ets transcription factors. *EMBO J.* 21, 5225– 5234. <https://doi.org/10.1093/emboj/cdf527>

Watanabe, N., Nogawa, M., Ishiguro, M., Maruyama, H., Shiba, M., Satake, M., Eto, K., & Handa, M. (2017). Refined methods to evaluate the in vivo hemostatic function and viability of transfused human platelets in rabbit models. *Transfusion*, 57, 2035–2044. <https://doi.org/10.1111/trf.14189>

Yamamoto, R., Morita, Y., Ooehara, J., Hamanaka, S., Onodera, M., Rudolph, K. L., Ema, H., & Nakauchi, H. (2013). Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. *Cell*, 154, 1112– 1126. <https://doi.org/10.1016/j.cell.2013.08.007>